Faculty Collaboration Database -

CURRICULUM VITAE

Marcelo C. Pasquini MD, MS

Professor
Department of Medicine
Division of Hematology and Oncology - Medicine
and
Senior Scientific Director for Clinical Trials
Department of Medicine
Center for International Blood and Marrow Transplant Research (CIBMTR®)


OFFICE ADDRESS:
Clinical Cancer Center
9200 W Wisconsin Ave
Milwaukee, WI 53226
Phone: 414-805-0700
Fax: 414-805-0714


EDUCATION:
08/1991 - 08/1997 M.D. (Diploma Medico), State University of Londrina (Universidade Estadual de Londrina), Londrina, Brazil
09/2004 - 05/2006 M.S., Epidemiology, Medical College of Wisconsin, Milwaukee, WI


POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:
06/1998 - 06/2001 Residency, Internal Medicine, Jackson Memorial Hospital, University of Miami, 1611 NW 12th Avenue, Miami, FL 33136
07/2001 - 06/2004 Fellowship, Hematology and Oncology, University of Utah, 30 N 1900 E, Room 5C402, Salt Lake City, UT 84132
07/2004 - 06/2005 Fellowship, Medicine, Neoplastic Diseases and Related Disorders, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226


FACULTY APPOINTMENTS:
08/2005 - 08/2008 Staff Physician, Consultant Care, Hematology and Oncology, Clement J. Zablocki Veterans Affairs Medical Center, 5000 West National Avenue, Milwaukee, WI 53295
08/2005 - 06/2012 Assistant Professor, Department of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin, 9200 West Wisconsin Avenue, Milwaukee, WI 53226
07/2012 - Present Associate Professor of Medicine, Department of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin, 9200 West Wisconsin Avenue, Milwaukee, WI 53226


RESEARCH ADMINISTRATIVE APPOINTMENTS:
08/2005 - Present Protocol Officer, Blood and Marrow Transplant Clinical Trials Network (BMT CTN), Department of Medicine, Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, 9200 W. Wisconsin Avenue, CCC, Suite C5500, 5th Floor, Milwaukee, WI 53226
08/2005 - 06/2012 Assistant Scientific Director, Department of Medicine, Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, 9200 W. Wisconsin Avenue, CCC, Suite C5500, 5th Floor, Milwaukee, WI 53226
08/2005 - Present Clinical Trial Medical Monitor, Blood and Marrow Transplant Clinical Trials Network (BMT CTN), Department of Medicine, Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, 9200 West Wisconsin Avenue, CCC, Suite C5500, 5th Floor, Milwaukee, WI 53226
07/2012 - 10/2013 Associate Scientific Director, Department of Medicine, Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, 9200 West Wisconsin Avenue, Suite C5500, Milwaukee, WI 53226
11/2013 - Present Senior Scientific Director for Clinical Trials and Cellular Therapy, Department of Medicine, Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, 9200 West Wisconsin Avenue, CCC, Suite C5500, 5th Floor, Milwaukee, WI 53226


HOSPITAL STAFF PRIVILEGES:
08/2005 - 08/2008 Staff Phyician, Hematology and Oncology, Clement J. Zablocki Veterans Affairs Medical Center, 5000 W. National Avenue, Milwaukee, WI 53295
08/2005 - Present Associate Professor of Medicine, Department of Medicine, Hematology and Oncology, Medical College of Wisconsin, Froedtert Memorial Lutheran Hospital, 9200 W. Wisconsin Avenue, Milwaukee, WI 53226


SPECIALTY BOARDS AND CERTIFICATION:


Board Certified	Issue Date	Expiration
American Board of Internal Medicine (ABIM)	08/2001	12/2011
ABIM - Clinical Oncology	11/2004	12/2014
ABIM - Hematology	11/2005	12/2026


Licensure	Number	Issue Date	Expiration
Wisconsin Medical License	47202-20	07/21/2004	10/31/2019


AWARDS AND HONORS:
06/2001 Eric Reiss Award for Outstanding Teaching, Internal Medicine Residency, Jackson Memorial Hospital, University of Miami
12/2003 American Society of Hematology Travel Award, American Society of Hematology
10/2014 Purple Heart Award from the BMT CTN. Excellence award given to investigators in the BMT CTN for activities related to blood and marrow transplant clinical trials., Blood and Marrow Clinical Trials Network (BMT CTN)


MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:
11/2001 - Present American Society of Hematology
01/2002 - Present American Society of Clinical Oncology
01/2004 - Present American Society of Blood and Marrow Transplantation
05/2008 - 05/2010 International Society of Cellular Therapy


EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:
Journal Review
2010 - Present Bone Marrow Transplantation
2010 - Present Biology of Blood and Marrow Transplantation
2013 - Present Blood
2015 - Present British Journal of Haematology
2015 - Present PLOS One
2015 - Present American Journal of Hematology


NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:
2010 - 2012 Member, Global Affairs Task Force, Foundation for the Accreditation of Cellular Therapy (FACT)
2012 - 2014 Data Safety Monitoring Board Reviewer (DSMB), Phase I Clinical Trial of Mesenchymal Cells Infusion for Treatment of Multiple Sclerosis - P.I. Jeffrey Cohen, MD - Cleveland Clinic, Cleveland, OH, Blood and Marrow Transplant Clinical Trials Network (BMT CTN)
2012 - 2016 Member, Choosing Wisely Task Force, American Society of Hematology (ASH)
2013 - 2015 Data Safety Monitoring Board Reviewer (DSMB), Extended Dose of TBI followed by Allo SCT for the Treatment of Refractory Acute LK and Advanced MDS - P.I. Mitchell Sabloff, MS, MDCM-The Ottawa Hospital, Canada, Blood and Marrow Transplant Clinical Trials Network (BMT CTN)
2013 - 2015 Member, National Marrow Donor Program New Technologies & Opportunities Advisory Group, National Marrow Donor Program (NMDP)
2013 - Present Consultant, GVHD Adjudication Committee, A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-center, phase 3 study of the safety, tolerability and efficacy of CMX 001 for prevention of CMV infection in CMV + HCT Recipients (CMX001-301), Chimerix, Inc.
2014 - 2016 Data Safety Monitoring Board Reviewer (DSMB), Pilot Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached To TCRζ and 4-1BB Signaling Domains Coupled with Salvage Autologous Stem-Cell Transplantation (ASCT) in Multiple, University of Pennsylvania
2014 - Present Abstract Reviewer, Abstract Submission Team, American Society of Hematology (ASH)
2016 - Present Chair, Data Safety Monitoring Committee (DSMC), OSU-15004 P Phase Ib Trial of Ar-42 with Pomalidomide in Relapsed Multiple Myeloma, The Ohio State University

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:


Active
Peer Review
Title:	U10 HL069294 BMT Clinical Research Network Data Coordinating Center
Source:	NIH/NHLBI
Role:	Co-Investigator. The DCC includes three organizations, CIBMTR, National Marrow Donor Program (NMDP) and The EMMES Corporation. Dr. Horowitz is the PI of this DCC grant. I am a Co-Investigator on this grant and the alternate CIBMTR representative on all DCC activities.
PI:	Mary M. Horowitz, MD, MS
Dates:	09/30/2001 - 06/30/2018
Direct Funds:	$42,609,749

Title:	U24 CA076518 A Data Resource for Analyzing Blood and Marrow Transplants
Source:	NIH/NCI
Role:	Co-Investigator. This Grant supports the transplant registries activities. My roles are Senior Scientific Director of two working committees, management of several corporate studies, coordinator of data sharing with the BMT CTN and development of the Cellular Therapy Registry.
PI:	Mary M. Horowitz, MD, MS
Dates:	05/15/2003 - 02/28/2018
Direct Funds:	$15,137,342

Title:	1U24HL138660 BMT Clinical Research Network Data Coordinating Center
Source:	NIH/NHLBI
Role:	Co-Investigator. The DCC includes three organizations, CIBMTR, National Marrow Donor Program (NMDP) and The EMMES Corporation. Dr. Horowitz is the PI of this DCC grant. I am a Co-Investigator on this grant and the alternate CIBMTR representative on all DCC activities.
PI:	Mary M. Horowitz, MD, MS
Dates:	09/15/2017 - 08/31/2024
Direct Funds:	$42,609,749

Title:	Stem Cell Therapeutic Outcomes Database
Source:	HRSA
Role:	Co-Investigator. My role in the SCTOD grant is to organize and develop the Cellular Therapy Registry.
PI:	J. Douglas Rizzo, MD, MS
Dates:	09/27/2017 - 09/26/2022
Direct Funds:	$18,590,285


Pending
Non-Peer Review
Title:	BMT CTN ViraCyte
Source:	NMDP via ViraCyte
Role:	Principal Investigator. As principal investigator I directed a team of investigators to develop a multi-center clinical trial.
PI:	Marcelo C. Pasquini, MD, MS
Dates:	04/01/2017 - 06/30/2017
Direct Funds:	$26,809

Title:	BMT CTN 1602 High Risk Acute GVHD
Source:	NMDP via Gilead Sciences Inc.
Role:	Principal Investigator. As principal investigator, I directed a team of investigators to develop a multi-center clinical trial.
PI:	Marcelo C. Pasquini, MD, MS
Dates:	05/01/2017 - 04/30/2022
Direct Funds:	$723,633

Title:	Novartis Cellular Therapy CTL019 Registry
Source:	Novartis
Role:	Principal Investigator. As principal investigator, I developed a long-term follow-up protocol for collection of data from recipients of CAR-T Cells, which requires 15 years of follow-up by the FDA.
PI:	Marcelo C. Pasquini, MD, MS
Dates:	05/01/2017 - 10/31/2021
Direct Funds:	$11,928,814


Prior
Peer Review
Title:	HHSH250201200016C Stem Cell Therapeutic Outcomes Database (SCTOD)
Source:	HRSA
Role:	Co-Investigator. My role in the SCTOD grant is to organize and develop the Cellular Therapy Registry.
PI:	J. Douglas Rizzo, MD, MS
Dates:	09/27/2006 - 09/26/2017
Direct Funds:	$16,576,695

Title:	2 R01 CA083724 - Chromosomal Abnormalities in Myeloma as Detected by FISH
Source:	NIH/NCI
Role:	Co-Investigator
Dates:	03/01/2009 - 01/31/2014
Direct Funds:	$68,070

Title:	1 R01 HL102278-A1 Genetic Susceptibility to Unrelated Donor Stem Cell Transplant-Related Mortality
Source:	NIH/NHLBI
Role:	Co-Principal Investigator
PI:	Marcelo C. Pasquini, MD, MS; Theresa Hahn, PhD and Lara Sucheston, MD
Dates:	07/05/2010 - 06/30/2014
Direct Funds:	$54,313

Title:	R01 HL107213 Prognostic Immunophenotyping in Myeloma Treatment with Novel Agents (PRIMeR) Study
Source:	NIH/NHLBI
Role:	Co-Principal Investigator. As Co-principal investigator of this project, I managed this is ancillary trial of a clinical trial for the treatment of Multiple Myeloma. The trial data was released in the Fall of 2017 and is now being analyzed.
PI:	Marcelo C. Pasquini, MD, MS and Theresa Hahn
Dates:	06/01/2011 - 03/31/2016
Direct Funds:	$1,287,223


INVITED LECTURES/WORKSHOPS/PRESENTATIONS:
Local
Marcelo C. Pasquini, MD, MS, Treatment for Multiple Myeloma, Medical College of Wisconsin Department of Medicine Grand Rounds, Milwaukee, WI, 04/2014
Marcelo C. Pasquini, MD, MS, Myeloma: A History of the Disease and Standard Treatment, 12th Annual Multiple Myeloma Survivorship Conference, Leukemia & Lymphoma Society, Pewaukee, WI, 09/2014
Marcelo C. Pasquini, MD, MS, Acute GVHD: Biology, Staging and Treatment - Part I, BMT Education Session, Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, 08/18/2016
Marcelo C. Pasquini, MD, MS, Acute GVHD: Biology, Staging and Treatment - Part II, BMT Education Session, Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, 12/08/2016
Marcelo C. Pasquini, MD, MS, Cellular Therapy Registry Initiative, Hematological Malignancy & Immunotherapy Research Program, Cancer Center, Medical College of Wisconsin, Milwaukee, WI, 06/2017

Regional
Marcelo C Pasquini, MD, MS, What is HSCT and DCI? How and when to report? Differences in reporting donor cellular infusion data comparing with Hematopoietic stem cell transplantation, National Marrow Donor Program Council Meeting, Data Managers/Clinical Research Professionals Meeting, Minneapolis, MN, 10/2005
Marcelo C. Pasquini, MD, MS, Collection of AML data pre and post Hematopoietic, National Marrow Donor Program Council Meeting, Data Managers/Clinical Research Professionals Meeting, Minneapolis, MN, 10/2006
Marcelo C. Pasquini, MD, MS, Hematopoietic Cell Transplantation for Multiple Sclerosis, CIBMTR/EBMT Workshop *Dr. Pasquini designed and presented this workshop, Minneapolis, MN, 11/2008
Marcelo C. Pasquini, MD, MS, The Nuts and Bolts of Bone Marrow Transplants, 8th Annual Oncology Spring Forum: A Focus on Lymphoma, Wausau, WI, 04/2012

National
Pasquini, MC, Walker DM, DeHart SL, Tsai S, Cloning and Characterization of Human Penumbra: A Gene Encoding a New Erythroid Membrane Protein that Modulates the Proliferation and Adhesion of Proerythroblasts/Erythroblasts, American Society of Hematology Annual Meeting, San Diego, CA, 12/2003
Marcelo C. Pasquini, MD, MS, Collection of AML data pre and post Hematopoietic Stem Cell Transplantation, 2006 BMT Tandem Transplant Meetings, Data Managers/Clinical Research Professionals Meeting, Honolulu, HI, 02/2006
Nietfeld JJ, Pasquini MC, Logan BR, Verter F, Horowitz MH, Likelihood of Hematopoietic Stem Cell Transplantation in United States, BMT Tandem Meetings, Keystone, CO, 02/2007
Marcelo C. Pasquini, MD, MS, Conditioning Regimen Intensities, 2007 BMT Tandem Meetings, Clinical Research Professionals Meeting, Keystone, CO, 02/2007
Marcelo C. Pasquini, MD, MS, Basic Overview of Diseases Treated with Hematopoietic Stem Cell Transplantation, Data Managers/Clinical Research Professionals Meeting, 2008 BMT Tandem Meetings, San Diego, CA, 02/2008
Marcelo C. Pasquini, MD, MS, Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy Versus Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients with Multiple Myeloma, BMT CTN Investigator's Meeting, 2008 BMT Tandem Transplant Meetings, San Diego, CA, 02/2008
Marcelo C. Pasquini, MD, MS, Scope of Hematopoietic Cell Transplantation: Overview of an Evolving Therapy, Data Managers/Clinical Research Professionals Meeting, 2008 BMT Tandem Meeting, San Diego, CA, 02/2008
Marcelo C. Pasquini, MD, MS, Report on the BMT CTN 0102 Multiple Myeloma Clinical Trial, BMT CTN Investigators Meeting, 2008 BMT Tandem Meeting, San Diego, CA, 02/2008
Marcelo C. Pasquini, MD, MS, Hematopoietic Cell Transplantation, 2009 Roswell Park Cancer Institute Hematology Oncology Review, Buffalo, NY, 01/2009
Marcelo C. Pasquini, MD, MS, Development of Cellular Therapy Registry. 2009 BMT Tandem Meeting, Data Managers/Clinical Research Professionals Meeting, Tampa, FL, 02/2009
Marcelo C. Pasquini, MD, MS, Hematopoietic Cell Transplantation, 2010 Roswell Park Cancer Institute Hematology Oncology Review, Buffalo, NY, 01/2010
Marcelo C. Pasquini, MD, MS, Ancillary studies in the BMT CTN, 2010 BMT Tandem Meeting/ BMT CTN Clinical Coordinators Meeting, Orlando, FL, 02/2010
Pasquini, MC, Foley A, Carter S, Confer D, Horowitz MM, Gurgol C, Giralt S, Shilsky R, McCarthy P, Maximizing Accrual to Transplant Trials in Multiple Myeloma Lessons from the Blood and Marrow Transplant Clinical Trials Network, Eastern Cooperative Oncology Group, and Cancer and Leukemia Group B Collaboration, ASCO/NCI Symposium on Clinical Trial Accrual, Rockville, MD, 04/2010
Pasquini, MC, Pirog S, Baldomero H, Sobocinski K, Keating A, Hare J, Loper K, Laughlin M, Horwitz E, Heslop H, Cellular Therapy for Regenerative Medicine: Activity in the US During 2008, International Society for Cellular Therapy (ISCT) Annual Meeting, Philadelphia, PA, 05/2010
Marcelo C. Pasquini, MD, MS, Comorbidities in Transplantation, 2011 BMT Tandem Meeting/ BMT CTN Clinical Coordinators Meeting, Honolulu, HA, 02/2011
Marcelo C. Pasquini, MD, MS, Clinical Outcomes/Transplant Results, 1st Annual Mentoring Program for Stem Cell Transplant Fellows, Atlanta, GA, 01/2012
Marcelo C. Pasquini, MD, MS, BMT CTN Open Protocols, 2012 BMT Tandem Meetings/ BMT CTN Coordinators Meeting, San Diego, CA, 02/2012
Marcelo C. Pasquini, MD, MS, BMT CTN Cellular Therapy for Regenerative Medicine & More, 2012 BMT Tandem Meetings, San Diego, CA, 02/2012
Marcelo C. Pasquini, MD, MS, Overview of CIBMTR Data Collection for Cellular Therapy Indications, Remaining Challenges, HHS Advisory Council on Blood Stem Cell Transplantation, Washington, DC, 05/2012
Marcelo C. Pasquini, MD, MS, Transplants for Autoimmune Diseases, National Marrow Donor Program Annual Council Meeting, Minneapolis, MN, 10/2013
Pasquini, MC, Georges, G, Co-presenter, Autoimmune Disease: A New Application for Hematopoietic Cell Transplantation, National Marrow Donor Program Annual Council Meeting, Minneapolis, MN, 11/2013
Horowitz, MM and Pasquini, MC, Center for International Blood and Marrow Transplant Research (CIBMTR) Cellular Therapy Registry, Presentation for the Cancer Therapy Evaluation Program, NIH, Rockville, MD, 04/06/2016
Horowitz, MM and Pasquini, MC, Overview of the Blood and Marrow Clinical Trials Network (BMT CTN) and the Center for International Blood and Marrow Transplant Research (CIBMTR), Presentation for the NIH/NCI, Rockville, MD, 08/10/2016

International
Marcelo C. Pasquini, MD, MS, Workshop on Clinical Research in Transplantation, X Meeting of the Brazilian Society of Bone Marrow Transplantation, Curitiba, Brazil, 08/2006
Marcelo C. Pasquini, MD, MS, Hematopoietic Stem Transplantation for Rare Benign Hematopoietic Disorders, X Meeting of the Brazilian Society of Bone Marrow Transplantation, Curitiba, Brazil, 08/2006
Marcelo C. Pasquini MD, MS, Conditioning Regimen Intensity in Transplantation, XI Meeting of the Brazilian Society of Bone Marrow Transplantation, Gramado, Brazil, 08/2007
Marcelo C. Pasquini MD, MS, II Workshop in Clinical Research in Transplantation, XI Meeting of the Brazilian Society of Bone Marrow Transplantation, Gramado, Brazil, 08/2007
Marcelo C. Pasquini, MD, MS, Hematopoietic Stem Cell Transplantation for Autoimmune Diseases in North and South America, 2008 EBMT Annual Meeting, Florence, Italy, 04/2008
Marcelo C. Pasquini, MD, MS, Acute Myeloid Leukemia, Hospital Israelita Albert Einstein/MD Anderson Board Review Course, Sao Paulo, Brazil, 06/2008
Marcelo C. Pasquini, MD, MS, Importance of Transplant Registries in Clinical Research, Albert Einstein Jewish Hospital/MD Anderson Cancer Center Hematology Oncology Board Review Course, Sao Paulo, Brazil, 06/2008
Marcelo C. Pasquini, MD, MS, Hematopoietic Cell Transplantation, XII Meeting of the Brazilian Society of Bone Marrow Transplantation, São Paulo, Brazil, 09/2008
Marcelo C. Pasquini, MD, MS, Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Risk Factors for post-transplant mortality, XII Meeting of the Brazilian Society of None Marrow Transplantation, São Paulo, Brazil, 09/2008
Marcelo C. Pasquini, MD, MS, Epidemiology of Hematopoietic Cell Transplantation for Myelofibrosis, XII Meeting of the Brazilian Society of None Marrow Transplantation, São Paulo, Brazil, 09/2008
Marcelo C. Pasquini, MD, MS, Hematopoietic cell transplantation for autoimmune diseases reported to the CIBMTR, 2009 European Group for Blood and Marrow Transplant (EBMT) Annual Meeting, Goteborg, Sweden, 04/2009
Marcelo C. Pasquini, MD, MS, Gisela Tunes Silva, PhD, Statistical Analysis of Studies in Hematopoietic Cell Transplantation, XIII Meeting of the Brazilian Society of Bone Marrow Transplantation/XII Brazilian National Meeting of Immunogenetics and Histocompatibility, Curitiba, Brazil, 08/2009
Marcelo C. Pasquini, MD, MS, Hematopoietic Cell Transplantation in Latin America, XIII Meeting of the Brazilian Society of Bone Marrow Transplantation, Curitiba, Brazil, 08/2009
Marcelo C. Pasquini, MD, MS, Cellular Therapy for Regenerative Medicine: Basic Concepts and Clinical Applications, XIII Meeting of the Brazilian Society of Bone Marrow Transplantation, Curitiba, Brazil, 08/2009
Marcelo C. Pasquini, MD, MS, Università degli Studi di Firenze, Haematopoietic Stem Cell Transplantation for Severe Autoimmune Diseases, Florence, Italy, 11/2009
Marcelo C. Pasquini, MD, MS, Hematopoietic Stem Cell Transplantation for Autoimmune Diseases: EBMT AND CIBMTR Projects, 2010 EBMT Annual Meeting, Vienna, Austria, 03/2010
Marcelo C. Pasquini, MD, MS, HLA-matched Sibling versus Unrelated Donor Hematopoietic Cell Transplantation for Follicular Lymphoma, 2010 EBMT Annual Meeting, Vienna, Austria, 03/2010
Marcelo C. Pasquini, MD, MS, Haploidentical Hematopoietic Cell Transplantation, 2010 Albert Einstein Jewish Hospital/MD Anderson Cancer Center Hematology Oncology Board Review Course, São Paulo, Brazil, 06/2010
Marcelo C. Pasquini, MD, MS, Acute Myeloid Leukemia Overview, 2010 Albert Einstein Jewish Hospital/MD Anderson Cancer Center Hematology Oncology Board Review Course, São Paulo, Brazil, 06/2010
Marcelo C. Pasquini, MD, MS, Regimen Related Toxicity and Patient Selection in Transplantation, XIV Meeting of the Brazilian Society of Bone Marrow Transplantation, Porto de Galinhas, Brazil, 08/2010
Marcelo C. Pasquini, MD, MS, Hematopoietic Cell Transplantation for Hemoglobinopathies, XIV Meeting of the Brazilian Society of Bone Marrow Transplantation, Porto de Galinhas, Brazil, 08/2010
Marcelo C. Pasquini, MD, MS, How to collaborate with International Registries? What is the Benefit?, 15th Congress of the Asia Pacific Blood and Marrow Transplantation (APBMT), Phuket, Thailand, 10/2010
Marcelo C. Pasquini, MD, MS, Importance of National and International Transplant Registries, Second Venezuelan Symposium on Bone Marrow Transplantation, Valencia, Venezuela, 10/2010
Marcelo C. Pasquini, MD, MS, Hematopoietic Cell Transplantation in the Elderly, Second Venezuelan Symposium on Bone Marrow Transplantation, Valencia, Venezuela, 10/2010
Marcelo C. Pasquini, MD, MS, Development of Cellular Therapy Registry, Workshop on Mesenchymal Stromal Cells Isolation and Good Manufacturing Practices, Curitiba, Brazil, 12/2010
Marcelo C. Pasquini, MD, MS, What is the Future of Autologous Transplant for Acute Myeloid Leukemia?, XV Meeting of the Brazilian Society of Bone Marrow Transplantation, Rio de Janeiro, Brazil, 08/2011
Marcelo C. Pasquini, MD, MS, Allogeneic Hematopoietic cell Transplantation for Multiple Myeloma, XV Meeting of the Brazilian Society of Bone Marrow Transplantation, Rio de Janeiro, Brazil, 08/2011
Marcelo C. Pasquini, MD, MS, Accreditation of Transplant Centers, XV Meeting of the Brazilian Society of Bone Marrow Transplantation, Rio de Janeiro, Brazil, 08/2011
Marcelo C. Pasquini, MD, MS, Patient Selection and Transplant Indications, Workshop Session Chair, 1st International of Hematopoietic Cell Transplantation in Emerging Countries, WBMT Workshop on Transplantation in Emerging Health System, Hanoi, Vietnam, 11/2011
Marcelo C. Pasquini, MD, MS, Transplant Outcome Registries, Workshop Session Chair, 1st International of Hematopoietic Cell Transplantation in Emerging Countries, WBMT Workshop on Transplantation in Emerging Health System, Hanoi, Vietnam, 11/2011
Marcelo C. Pasquini, MD, MS, Transplants for Leukemias, 1st International of Hematopoietic Cell Transplantation in Emerging Countries, Worldwide Network for Blood & Marrow Transplantation (WBMT) Scientific Session, Hanoi, Vietnam, 11/2011
Marcelo C. Pasquini, MD, MS, Comparison of Hematopoietic Cell Transplantation with CD34-selected T-Cell Depletion to Unmanipulated Grafts for AML" during Miltenyi Symposium, Cellular Therapy: Exciting Developments in Stem Cell Transplantation during the 38th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT), Geneva, Switzerland, 04/2012
Marcelo C. Pasquini, MD, MS, The Issue of SCT in TKI Era during the symposium CML Treatment in Developing Countries, XXXIV World Congress International Society of Hematology (ISH), Cancun, Mexico, 04/2012
Marcelo C. Pasquini, MD, MS, Stem Cell Grafting in Latin America, during the symposium Stem Cell Grafting in Developing Countries, XXXIV World Congress International Society of Hematology (ISH), Cancun, Mexico, 04/2012
Marcelo C. Pasquini, MD, MS, Hematopoietic Cell Transplantation in AML: T-cell Depletion versus Unmanipulated Grafts for the Prevention of GVHD, during the Arising Potency of Cellular Therapies Session, Miltenyi Biotec Corporate Symposia and Tutorial Program, 18th Annual Meeting of the International Society for Cellular Therapy, Seattle, WA, 06/2012
Marcelo C. Pasquini, MD, MS, Facilitator/Organizer, Workshop on Cellular Therapy and Transplantation for Autoimmune Diseases, Milwaukee, WI, 04/2013
Marcelo C. Pasquini, MD, MS, Allogeneic Transplants for Multiple Myeloma in the Era of Novel Agents, XVII Congresso da Sociedade Brasileira de Transplante de Medula Óssea, São Paulo, Brazil, 08/2013
Marcelo C. Pasquini, MD, MS, Cellular Therapies: Perspective from the CIBMTR, XVII Congresso da Sociedade Brasileira de Transplante de Medula Óssea, São Paulo, Brazil, 08/2013
Marcelo C. Pasquini, MD, MS, Controversies in Transplant: In vitro T-cell Depletion, The 2nd International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM), Berlin, Germany, 10/2013
Marcelo C. Pasquini, MD, MS, Outcomes Database in Transplant Research – Presentation and Chairman for the Round Table Discussion, 2nd Workshop of the Worldwide Network for Blood and Marrow Transplantation in collaboration with the World Health Organization, Salvador, Brazil, 10/2013
Marcelo C. Pasquini, MD, MS, Transplantation for Mulitiple Myeloma, Worldwide Network for Blood and Marrow Transplantation Scientific Symposium, Salvador, Brazil, 10/2013
Marcelo C. Pasquini, MD, MS, Facilitator/Organizer, 2nd Workshop of the Worldwide Network for Blood and Marrow Transplantation in collaboration with the World Health Organization, Salvador, Brazil, 10/2013
Marcelo C. Pasquini, MD, MS, BMT for Multiple Myeloma in 2014, XVIII Congress of the Congresso da Sociedade Brasileira de Transplante de Medula Óssea, Belo Horizonte, Brazil, 08/2014
Marcelo C. Pasquini, MD, MS, Prophylaxis Strategies, Acute GVHD Roundtable, XVIII Congresso da Sociedade Brasileira de Transplante de Medula Óssea, Belo Horizonte, Brazil, 08/2014
Marcelo C. Pasquini, MD, MS, Panelist, Roundtable discussion: Developing the AFBMT, 3rd Workshop of the Worldwide Network for Blood and Marrow Transplantation in cooperation with the World Health Organization, Cape Town, South Africa, 11/2014
Marcelo C. Pasquini, MD, MS, Co-Chair, Patient/donor Registration and Outcome Database Session, 3rd Workshop of the Worldwide Network for Blood and Marrow Transplantation in cooperation with the World Health Organization, Cape Town, South Africa, 11/2014
Marcelo C. Pasquini, MD, MS, Moderator, Roundtable Discussion: Gain experience with autologous HCT or begin with allogeneic HCT – where the need may be greatest?, 3rd Workshop of the Worldwide Network for Blood and Marrow Transplantation in cooperation with the World Health Organization, Cape Town, South Africa, 11/2014
Marcelo C. Pasquini, MD, MS, Moderator, Clinical Allogeneic Transplantation: Results: Haploidentical and Beyond, Oral Abstracts Session, 56th Annual Meeting of the American Society of Hematology, San Francisco, CA, 12/2014
Marcelo C. Pasquini, MD, MS, Overview for Cell Therapy Data Collection Initiatives from CIBMTR, 41st Annual Meeting of the European Group for Blood and Marrow Transplantation, Istanbul, Turkey, 03/2015
Marcelo C. Pasquini, MD, MS, Center for International Blood and Marrow Transplant Research (CIBMTR): Outcomes Database and Research Organization for the Advancement of the Transplant Field, 2015 Joint Annual Congress of the Hematology Society of Taiwan and Taiwan Society of Blood and Marrow Transplantation, Taipei, Taiwan, 04/2015
Marcelo C. Pasquini, MD, MS, Chair: Joint Scientific Sessions: Latin American Bone Marrow Transplantation Group (LABMT) and CIBMTR (Center for Blood and Marrow Transplant Research), 19th SBTMO Congress 2015, Iguassu Falls, Brazil, 08/2015
Marcelo C. Pasquini, MD, MS, Clinical Trials: Considerations, CIBMTR Workshop on Statistics and Hematopoetic Stem Cell Transplantation: What Do We Need to Know?/19th SBTMO Congress 2015, Iguassu Falls, Brazil, 08/2015
Marcelo C. Pasquini, MD, MS, Are All Conditioning Regimens for Lymphoma the Same?, Scientific Sessions: Non-Hodgkin Lymphomas/19th SBTMO 2015, Iguassu Falls, Brazil, 08/2015
Marcelo C. Pasquini, MD, MS, Introduction, CIBMTR Workshop on Statistics and Hematopoetic Stem Cell Transplantation: What Do We Need to Know?/19th SBTMO Congress 2015, Iguassu Falls, Brazil, 08/2015
Marcelo C. Pasquini, MD, MS, Chair: Plenary Sessions: Stem Cell Transplantaion for Auto-immune Diseases: Patient Selection, Stem Cell Mobilization, Prepatory Regimens and Supportive Care, 19th SBTMO Congress 2015, Iguassu Falls, Brazil, 08/2015
Marcelo C. Pasquini, MD, MS, The Role of Novel Agents as Consolidation and Maintenance Therapy Following Autologous Stem Cell Transplantation, Scientific Sessions: Multiple Myeloma: Novel Agents for Transplantation and Future Directions/19th SBTMO Congress 2015, Iguassu Falls, Brazil, 08/2015
Marcelo C. Pasquini, MD, MS, Did We Make Any Progress in Prevention of Acute and Chronic GVHD?, The 3rd International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM), Berlin, Germany, 10/2015
Marcelo C. Pasquini, MD, MS, Clinical Studies in Diseases other than MS: An Overview; What is the Modern Concept of the Transplant Paradigm? Issues of Mortality in Malignant and Non-Malignant Disease?, International Conference on Cell-Based Therapies for Multiple Sclerosis, Lisbon, Portugal, 11/2015
Marcelo C. Pasquini, MD, MS, Acute GVHD: Biology and Treatment, XX Congress of the Brazilian Society of Bone Marrow Transplantation Meeting (SBTMO), Fortaleza, Brazil, 08/24/2016
Marcelo C. Pasquini, MD, MS, Cellular Therapy and Immunotherapy in Multiple Myeloma, XX Congress of the Brazilian Society of Bone Marrow Transplantation Meeting (SBTMO), Fortaleza, Brazil, 08/24/2016
Marcelo C. Pasquini, MD, MS, CIBMTR: Data Manager Training Course, XX Congress of the Brazilian Society of Bone Marrow Transplantation Meeting (SBTMO), Fortaleza, Brazil, 08/25/2016
Marcelo C. Pasquini, MD, MS, Cellular Therapy Registry Initiative, XX Congress of the Brazilian Society of Bone Marrow Transplantation Meeting (SBTMO), Fortaleza, Brazil, 08/27/2016
Marcelo C. Pasquini, MD, MS, Co-Chair, Workshop I: Establishing a Transplant Program in Emerging Countries – Part 2, 4th Workshop and Scientific Symposium of the Worldwide Network for Blood & Marrow Transplantation (WBMT), Riyadh, Saudi Arabia, 01/15/2017
Marcelo C. Pasquini, MD, MS, Moderator, Roundtable Discussion: Getting Started and Containing Cost, 4th Workshop and Scientific Symposium of the Worldwide Network for Blood & Marrow Transplantation (WBMT), Riyadh, Saudi Arabia, 01/15/2017
Marcelo C. Pasquini, MD, MS, Panelist, EMBMT Registry, Moving Forward with Extended Reporting to EMBMT, 4th Workshop and Scientific Symposium of the Worldwide Network for Blood & Marrow Transplantation (WBMT), Riyadh, Saudi Arabia, 01/16/2017
Marcelo C. Pasquini, MD, MS, Co-Chair, EBMT & European Institutions: Working towards the Accelerated Development of Cellular Therapies to Tackle Cancer and Other Debilitating Disorders of the Hematopoietic System", 43rd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), Marseille, France, 03/27/2017


COMMITTEE SERVICE:
Medical College of Wisconsin
01/2007 - 08/2010 Member, Hematology/Oncology Fellowship Committee, Division of Neoplastic Diseases and Related Disorders, Department of Medicine, Medical College of Wisconsin
10/2008 - 08/2010 Member, Internal Medicine Resident Selection Committee, Department of Medicine, Medical College of Wisconsin
08/2010 - 08/2011 Scientific Review Committee, Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin
2012 - 2013 Planning Committee Member, Second Annual Controversies in Hematologic Malignancies Symposium, Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin
2013 - Present Facilitator, Adult Blood and Marrow Transplant Program Faculty Research Committee, Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin
2013 - 2014 Co-Program Director, Third Annual Controversies in Hematologic Malignancies Symposium, Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin
01/2014 - Present Council Member, Global Health Advisory Council, Institute for Health and Society, Global Health Program, Medical College of Wisconsin
03/2014 - Present Committee Member, Clinical Research Seed Grant Review Committee, Cancer Center, Department of Medicine, Medical College of Wisconsin
09/2014 - Present Member, Cellular Immunotherapy Committee, Division of Hematology and Oncology, Department of Medicine, Medical Collge of Wisconsin
04/2017 - Present Member, Clinical Program Leadership Committee, Cancer Center, Froedtert & Medical College of Wisconsin

Hospital
05/2005 - 05/2006 Member, Blood utilization Committee, Clement J. Zablocki Veterans Affairs Medical Center
08/2005 - 08/2008 Member, Cancer Committee, Clement J. Zablocki Veterans Affairs Medical Center


MEDICAL COLLEGE TEACHING ACTIVITIES:
Community/Lay Public
01/2007 - Present Lecture and Q&A about Myeloma. Leukemia Lymphoma Society, Multiple Myeloma Support Group
06/2009 - Present Lecture and Q&A about Myeloma. Leukemia Lymphoma Society, Multiple Myeloma Support Group

Medical Student Education
07/2006 - 08/2006 ACP Externship in Hematology/Oncology
02/2008 - 03/2008 Medical Student Instructor for the Clinical Examination and Reasoning (CER) course


MCW STUDENTS, FACULTY, RESIDENTS AND CLINICAL/RESEARCH FELLOWS MENTORED:
Medical Students
Steven Pirog, Medical College of Wisconsin, 06/2009 - 08/2009 Mentor, Student Summer Research Program
Sanghee Hong, Medical College of Wisconsin, 01/2011 - Present Mentor, Research Physician Track
Phillip Zhang, Medical College of Wisconsin, 06/2012 - Present Mentor, Student Summer Research Program
Nicholas T. Placone, Medical College of Wisconsin, 12/2014 - 06/2016 Mentor/Faculty Advisor

Clinical/Research Fellows
Tara Graf, MD, Medical College of Wisconsin, 07/2013 - 09/2013 Clinical Research Mentor
Larisa Broglie, MD, Medical College of Wisconsin, 07/2016 - 05/2018 Clinical Research Mentor

Residents
Medical College of Wisconsin, 08/2005 - 08/2008 Faculty, Internal Medicine Residency Program, Core Curriculum Lecture Series
Medical College of Wisconsin, 08/2006 - 08/2008 Faculty, Internal Medicine Residency Ambulatory Immersion Program

Faculty
Anita D'Souza, MD, Medical College of Wisconsin, 2015 - Present Faculty Mentorship Committee Member


EXTRAMURAL STUDENTS, FACULTY, RESIDENTS, AND CLINICAL/RESEARCH FELLOWS MENTORED:
Graduate Students
PhD Committees
Chanbin Guo, Medical College of Wisconsin, Thesis Committee for PhD in Biostatistics, 09/2009 - 08/2011
Shuyuan Mo, Medical College of Wisconsin, Thesis Committee for PhD in Biostatistics, 09/2009 - 08/2011

Faculty
Richard Olsson, MD, PhD, Karolinska University Hospital, 03/2010 - 12/2010 Research Mentor


BIBLIOGRAPHY
Refereed Journal Publications/Original Papers
1. Mathew P, Morris SW, Kane JR, Shurtleff SA, Pasquini M, Jenkins NA, Gilbert DJ, Copeland NG. Localization of the murine homolog of the anaplastic lymphoma kinase (AlK) gene on mouse chromosome 17. Cytogenet Cell Genet. 1995;70(1-2):143-4.
2. Roy V, Pérez WS, Eapen M, Marsh JC, Pasquini M, Pasquini R, Mustafa MM, Bredeson CN, Non-Malignant Marrow Disorders Working Committee of the International Bone Marrow Transplant Registry. Bone marrow transplantation for diamond-blackfan anemia. Biol Blood Marrow Transplant. 2005 Aug;11(8):600-8.
3. Chen Z, Pasquini M, Hong B, DeHart S, Heikens M, Tsai S. The human Penumbra gene is mapped to a region on chromosome 7 frequently deleted in myeloid malignancies. Cancer Genet Cytogenet. 2005 Oct 15;162(2):95-8.
4. Hari P, Pasquini MC, Vesole DH. Cure of multiple myeloma -- more hype, less reality. Bone Marrow Transplant. 2006 Jan;37(1):1-18.
5. Hari P, Pasquini MC, Vesole DH. New questions about transplantation in multiple myeloma. Oncology (Williston Park). 2006 Sep;20(10):1230-42; discussion 1242, 1244, 1249-50.
6. Kharfan-Dabaja MA, Abou Mourad YR, Fernandez HF, Pasquini MC, Santos ES. Hematopoietic cell transplantation in acute promyelocytic leukemia: a comprehensive review. Biol Blood Marrow Transplant. 2007 Sep;13(9):997-1004.
7. Schlenk RF, Pasquini MC, Pérez WS, Zhang MJ, Krauter J, Antin JH, Bashey A, Bolwell BJ, Büchner T, Cahn JY, Cairo MS, Copelan EA, Cutler CS, Döhner H, Gale RP, Ilhan O, Lazarus HM, Liesveld JL, Litzow MR, Marks DI, Maziarz RT, McCarthy PL, Nimer SD, Sierra J, Tallman MS, Weisdorf DJ, Horowitz MM, Ganser A, CIBMTR Acute Leukemia Working Committee. HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR. Biol Blood Marrow Transplant. 2008 Feb;14(2):187-96. PMCID: PMC2531160
8. Nietfeld JJ, Pasquini MC, Logan BR, Verter F, Horowitz MM. Lifetime probabilities of hematopoietic stem cell transplantation in the U.S. Biol Blood Marrow Transplant. 2008 Mar;14(3):316-22. PMCID: PMC2531159
9. Nietfeld JJ, Pasquini MC, Logan BR, Verter F, Horowitz MM. On the probability of using cord blood. Biol Blood Marrow Transplant. 2008 Jun;14(6):724-5.
10. Pasquini MC. Impact of graft-versus-host disease on survival. Best Pract Res Clin Haematol. 2008 Jun;21(2):193-204.
11. Pasquini R, Carreras J, Pasquini MC, Camitta BM, Fasth AL, Hale GA, Harris RE, Marsh JC, Robinson AJ, Zhang MJ, Eapen M, Wagner JE. HLA-matched sibling hematopoietic stem cell transplantation for fanconi anemia: comparison of irradiation and nonirradiation containing conditioning regimens. Biol Blood Marrow Transplant. 2008 Oct;14(10):1141-1147. PMCID: PMC2581414
12. Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, Sandmaier B. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009 Mar;15(3):367-9. PMCID: PMC3110087
13. Giralt S, Vesole DH, Somlo G, Krishnan A, Stadtmauer E, Mccarthy P, Pasquini MC, Blood and Marrow Transplant Clinical Trials Network Multiple Myeloma Working Group. Re: Tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. J Natl Cancer Inst. 2009 Jul 01;101(13):964; author reply 966-7. PMCID: PMC4415058
14. Alousi AM, Weisdorf DJ, Logan BR, Bolaños-Meade J, Carter S, Difronzo N, Pasquini M, Goldstein SC, Ho VT, Hayes-Lattin B, Wingard JR, Horowitz MM, Levine JE, Blood and Marrow Transplant Clinical Trials Network. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood. 2009 Jul 16;114(3):511-7. PMCID: PMC2713466
15. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, Apperley J, Slavin S, Pasquini M, Sandmaier BM, Barrett J, Blaise D, Lowski R, Horowitz M. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009 Dec;15(12):1628-33. PMCID: PMC2861656
16. Pasquini MC, Wang Z, Horowitz MM, Gale RP. 2010 report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders. Clin Transpl. 2010:87-105.
17. Litzow MR, Tarima S, Pérez WS, Bolwell BJ, Cairo MS, Camitta BM, Cutler CS, de Lima M, Dipersio JF, Gale RP, Keating A, Lazarus HM, Luger S, Marks DI, Maziarz RT, McCarthy PL, Pasquini MC, Phillips GL, Rizzo JD, Sierra J, Tallman MS, Weisdorf DJ. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood. 2010 Mar 04;115(9):1850-7. PMCID: PMC2832815
18. Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, Szer J, Lipton J, Schwendener A, Gratwohl M, Frauendorfer K, Niederwieser D, Horowitz M, Kodera Y, Worldwide Network of Blood and Marrow Transplantation. Hematopoietic stem cell transplantation: a global perspective. JAMA. 2010 Apr 28;303(16):1617-24. PMCID: PMC3219875
19. Pavletic SZ, Kumar S, Mohty M, de Lima M, Foran JM, Pasquini M, Zhang MJ, Giralt S, Bishop MR, Weisdorf D. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation. Biol Blood Marrow Transplant. 2010 Jul;16(7):871-90. PMCID: PMC2916039
20. Joshua TV, Rizzo JD, Zhang MJ, Hari PN, Kurian S, Pasquini M, Majhail NS, Lee SJ, Horowitz MM. Access to hematopoietic stem cell transplantation: effect of race and sex. Cancer. 2010 Jul 15;116(14):3469-76. PMCID: PMC3153958
21. Schriber J, Agovi MA, Ho V, Ballen KK, Bacigalupo A, Lazarus HM, Bredeson CN, Gupta V, Maziarz RT, Hale GA, Litzow MR, Logan B, Bornhauser M, Giller RH, Isola L, Marks DI, Rizzo JD, Pasquini MC. Second unrelated donor hematopoietic cell transplantation for primary graft failure. Biol Blood Marrow Transplant. 2010 Aug;16(8):1099-106. PMCID: PMC2897953
22. Pasquini MC, Griffith LM, Arnold DL, Atkins HL, Bowen JD, Chen JT, Freedman MS, Kraft GH, Mancardi GL, Martin R, Muraro PA, Nash RA, Racke MK, Storek J, Saccardi R. Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies. Biol Blood Marrow Transplant. 2010 Aug;16(8):1076-83. PMCID: PMC2897916
23. Navarro WH, Agovi MA, Logan BR, Ballen K, Bolwell BJ, Frangoul H, Gupta V, Hahn T, Ho VT, Juckett M, Lazarus HM, Litzow MR, Liesveld JL, Moreb JS, Marks DI, McCarthy PL, Pasquini MC, Rizzo JD. Obesity does not preclude safe and effective myeloablative hematopoietic cell transplantation (HCT) for acute myelogenous leukemia (AML) in adults. Biol Blood Marrow Transplant. 2010 Oct;16(10):1442-50. PMCID: PMC2933950
24. Horan JT, Logan BR, Agovi-Johnson MA, Lazarus HM, Bacigalupo AA, Ballen KK, Bredeson CN, Carabasi MH, Gupta V, Hale GA, Khoury HJ, Juckett MB, Litzow MR, Martino R, McCarthy PL, Smith FO, Rizzo JD, Pasquini MC. Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made? J Clin Oncol. 2011 Mar 01;29(7):805-13. PMCID: PMC3068057
25. Nishihori T, Kharfan-Dabaja MA, Ochoa-Bayona JL, Bazarbachi A, Pasquini M, Alsina M. Role of reduced intensity conditioning in allogeneic hematopoietic cell transplantation for patients with multiple myeloma. Hematol Oncol Stem Cell Ther. 2011;4(1):1-9.
26. Barker CC, Agovi MA, Logan B, Lazarus HM, Ballen KK, Gupta V, Hale GA, Frangoul H, Ho V, Rizzo JD, Pasquini MC, Regimen-Related Toxicity Writing Committee, Center for International Blood and Marrow Transplant Research. Childhood obesity and outcomes after bone marrow transplantation for patients with severe aplastic anemia. Biol Blood Marrow Transplant. 2011 May;17(5):737-44. PMCID: PMC3035737
27. Devine SM, Carter S, Soiffer RJ, Pasquini MC, Hari PN, Stein A, Lazarus HM, Linker C, Stadtmauer EA, Alyea EP 3rd, Keever-Taylor CA, O'Reilly RJ. Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303. Biol Blood Marrow Transplant. 2011 Sep;17(9):1343-51. PMCID: PMC3150599
28. Ahmed SO, Ghavamzadeh A, Zaidi SZ, Baldomero H, Pasquini MC, Hussain F, Alimoghaddam K, Almohareb F, Ayas M, Hamidieh A, Mahmoud HK, Elhaddad A, Ben Othman T, Abdelkefi A, Sarhan M, Abdel-Rahman F, Adil S, Alkindi S, Bazarbachi A, Benchekroun S, Niederwieser D, Horowitz M, Gratwohl A, El Solh H, Aljurf M. Trends of hematopoietic stem cell transplantation in the Eastern Mediterranean region, 1984-2007. Biol Blood Marrow Transplant. 2011 Sep;17(9):1352-61. PMCID: PMC3371191
29. Krishnan A, Pasquini MC, Logan B, Stadtmauer EA, Vesole DH, Alyea E 3rd, Antin JH, Comenzo R, Goodman S, Hari P, Laport G, Qazilbash MH, Rowley S, Sahebi F, Somlo G, Vogl DT, Weisdorf D, Ewell M, Wu J, Geller NL, Horowitz MM, Giralt S, Maloney DG, Blood Marrow Transplant Clinical Trials Network (BMT CTN). Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol. 2011 Dec;12(13):1195-203. PMCID: PMC3611089
30. Drobyski WR, Pasquini M, Kovatovic K, Palmer J, Douglas Rizzo J, Saad A, Saber W, Hari P. Tocilizumab for the treatment of steroid refractory graft-versus-host disease. Biol Blood Marrow Transplant. 2011 Dec;17(12):1862-8. PMCID: PMC3716013
31. Pasquini MC. Hematopoietic cell transplantation for chronic myeloid leukemia in developing countries: perspectives from Latin America in the post-tyrosine kinase inhibitor era. Hematology. 2012 Apr;17 Suppl 1:S79-82.
32. Eckrich M, Pasquini M. Hematopoietic cell transplantation in Latin America. Hematology. 2012 Apr;17 Suppl 1:S189-91.
33. Keever-Taylor CA, Devine SM, Soiffer RJ, Mendizabal A, Carter S, Pasquini MC, Hari PN, Stein A, Lazarus HM, Linker C, Goldstein SC, Stadtmauer EA, O'Reilly RJ. Characteristics of CliniMACS® System CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303. Biol Blood Marrow Transplant. 2012 May;18(5):690-7. PMCID: PMC3762249
34. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Schlossman R, Hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelly M, Seiler M, Rosenbaum C, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Anderson KC, Linker C. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012 May 10;366(19):1770-81. PMCID: PMC3744390
35. Saccardi R, Freedman MS, Sormani MP, Atkins H, Farge D, Griffith LM, Kraft G, Mancardi GL, Nash R, Pasquini M, Martin R, Muraro PA, European Blood and Marrow Transplantation Group, Center for International Blood and Marrow Research, HSCT in MS International Study Group. A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper. Mult Scler. 2012 Jun;18(6):825-34. PMCID: PMC3389500
36. Pasquini MC, Devine S, Mendizabal A, Baden LR, Wingard JR, Lazarus HM, Appelbaum FR, Keever-Taylor CA, Horowitz MM, Carter S, O'Reilly RJ, Soiffer RJ. Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation. J Clin Oncol. 2012 Sep 10;30(26):3194-201. PMCID: PMC3434978
37. Pasquini MC, Voltarelli J, Atkins HL, Hamerschlak N, Zhong X, Ahn KW, Sullivan KM, Carrum G, Andrey J, Bredeson CN, Cairo M, Gale RP, Hahn T, Storek J, Horowitz MM, McSweeney PA, Griffith LM, Muraro PA, Pavletic SZ, Nash RA. Transplantation for autoimmune diseases in north and South America: a report of the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2012 Oct;18(10):1471-8. PMCID: PMC3950896
38. Hicks LK, Bering H, Carson KR, Kleinerman J, Kukreti V, Ma A, Mueller BU, O'Brien SH, Pasquini M, Sarode R, Solberg L Jr, Haynes AE, Crowther MA. The ASH Choosing Wisely®campaign: five hematologic tests and treatments to question. Hematology Am Soc Hematol Educ Program. 2013;2013:9-14.
39. Pasquini M, Wang Z, Horowitz MM, Gale RP. 2013 report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders. Clin Transpl. 2013:187-97.
40. Giralt S, McCarthy PL, Anderson KC, Carter SL, Richardson PG, Rajkumar SV, Laport GG, Stadtmauer EA, Pasquini MC, Horowitz MM. Anatomy of a successful practice-changing study: a Blood and Marrow Transplantation Clinical Trials Network-National Cancer Institute Cooperative Group collaboration. Biol Blood Marrow Transplant. 2013 Jun;19(6):858-9. PMCID: PMC4426902
41. Akpek G, Pasquini MC, Logan B, Agovi MA, Lazarus HM, Marks DI, Bornhaeüser M, Ringdén O, Maziarz RT, Gupta V, Popat U, Maharaj D, Bolwell BJ, Rizzo JD, Ballen KK, Cooke KR, McCarthy PL, Ho VT. Effects of spleen status on early outcomes after hematopoietic cell transplantation. Bone Marrow Transplant. 2013 Jun;48(6):825-31. PMCID: PMC3606905
42. Gratwohl A, Baldomero H, Gratwohl M, Aljurf M, Bouzas LF, Horowitz M, Kodera Y, Lipton J, Iida M, Pasquini MC, Passweg J, Szer J, Madrigal A, Frauendorfer K, Niederwieser D, Worldwide Network of Blood and Marrow Transplantation (WBMT). Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study. Haematologica. 2013 Aug;98(8):1282-90. PMCID: PMC3729910
43. Cornell RF, Hari P, Zhang MJ, Zhong X, Thompson J, Fenske TS, Horowitz MM, Komorowski R, Palmer J, Pasquini MC, Rizzo JD, Saber W, Thomas M, Drobyski WR. Divergent effects of novel immunomodulatory agents and cyclophosphamide on the risk of engraftment syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2013 Sep;19(9):1368-73.
44. Bredeson C, LeRademacher J, Kato K, Dipersio JF, Agura E, Devine SM, Appelbaum FR, Tomblyn MR, Laport GG, Zhu X, McCarthy PL, Ho VT, Cooke KR, Armstrong E, Smith A, Rizzo JD, Burkart JM, Pasquini MC. Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation. Blood. 2013 Dec 05;122(24):3871-8. PMCID: PMC3854109
45. Hicks LK, Bering H, Carson KR, Kleinerman J, Kukreti V, Ma A, Mueller BU, O'Brien SH, Pasquini M, Sarode R, Solberg L Jr, Haynes AE, Crowther MA. The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question. Blood. 2013 Dec 05;122(24):3879-83.
46. Saad A, Mahindra A, Zhang MJ, Zhong X, Costa LJ, Dispenzieri A, Drobyski WR, Freytes CO, Gale RP, Gasparetto CJ, Holmberg LA, Kamble RT, Krishnan AY, Kyle RA, Marks D, Nishihori T, Pasquini MC, Ramanathan M, Lonial S, Savani BN, Saber W, Sharma M, Sorror ML, Wirk BM, Hari PN. Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. Biol Blood Marrow Transplant. 2014 Mar;20(3):402-408.e1. PMCID: PMC3961011
47. Kanate AS, Pasquini MC, Hari PN, Hamadani M. Allogeneic hematopoietic cell transplant for acute myeloid leukemia: Current state in 2013 and future directions. World J Stem Cells. 2014 Apr 26;6(2):69-81. PMCID: PMC3999783
48. Aplenc R, Zhang MJ, Sung L, Zhu X, Ho VT, Cooke K, Dvorak C, Hale G, Isola LM, Lazarus HM, McCarthy PL, Olsson R, Pulsipher M, Pasquini MC, Bunin N, Regimen-Related Toxicity Working Committee, Center for International Blood and Marrow Transplant Research. Effect of body mass in children with hematologic malignancies undergoing allogeneic bone marrow transplantation. Blood. 2014 May 29;123(22):3504-11. PMCID: PMC4041168
49. Holtan SG, Pasquini M, Weisdorf DJ. Acute graft-versus-host disease: a bench-to-bedside update. Blood. 2014 Jul 17;124(3):363-73. PMCID: PMC4102709
50. Alsina M, Becker PS, Zhong X, Adams A, Hari P, Rowley S, Stadtmauer EA, Vesole DH, Logan B, Weisdorf D, Qazilbash M, Popplewell LL, McClune B, Bensinger W, Riches M, Giralt SA, Pasquini MC, Resource for Clinical Investigation in Blood and Marrow Transplantation. Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014 Aug;20(8):1183-9. PMCID: PMC5036168
51. Aljurf M, Rizzo JD, Mohty M, Hussain F, Madrigal A, Pasquini MC, Passweg J, Chaudhri N, Ghavamzadeh A, Solh HE, Atsuta Y, Szer J, Kodera Y, Niederweiser D, Gratwohl A, Horowitz MM. Challenges and opportunities for HSCT outcome registries: perspective from international HSCT registries experts. Bone Marrow Transplant. 2014 Aug;49(8):1016-21.
52. Cutler C, Logan B, Nakamura R, Johnston L, Choi S, Porter D, Hogan WJ, Pasquini M, MacMillan ML, Hsu JW, Waller EK, Grupp S, McCarthy P, Wu J, Hu ZH, Carter SL, Horowitz MM, Antin JH. Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. Blood. 2014 Aug 21;124(8):1372-7. PMCID: PMC4141519
53. Bolaños-Meade J, Logan BR, Alousi AM, Antin JH, Barowski K, Carter SL, Goldstein SC, Hexner EO, Horowitz MM, Lee SJ, Levine JE, MacMillan ML, Martin PJ, Mendizabal AM, Nakamura R, Pasquini MC, Weisdorf DJ, Westervelt P, Ho VT. Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. Blood. 2014 Nov 20;124(22):3221-7; quiz 3335. PMCID: PMC4239331
54. Dhakal B, Strouse C, D'Souza A, Arce-Lara C, Esselman J, Eastwood D, Pasquini M, Saber W, Drobyski W, Rizzo JD, Hari PN, Hamadani M. Plerixafor and abbreviated-course granulocyte colony-stimulating factor for mobilizing hematopoietic progenitor cells in light chain amyloidosis. Biol Blood Marrow Transplant. 2014 Dec;20(12):1926-31.
55. Hicks LK, Bering H, Carson KR, Haynes AE, Kleinerman J, Kukreti V, Ma A, Mueller BU, O'Brien SH, Panepinto JA, Pasquini MC, Rajasekhar A, Sarode R, Wood WA. Five hematologic tests and treatments to question. Blood. 2014 Dec 04;124(24):3524-8.
56. Hicks LK, Bering H, Carson KR, Haynes AE, Kleinerman J, Kukreti V, Ma A, Mueller BU, O'Brien SH, Panepinto JA, Pasquini MC, Rajasekhar A, Sarode R, Wood WA. Five hematologic tests and treatments to question. Hematology Am Soc Hematol Educ Program. 2014 Dec 05;2014(1):599-603.
57. Howard CA, Fernandez-Vina MA, Appelbaum FR, Confer DL, Devine SM, Horowitz MM, Mendizabal A, Laport GG, Pasquini MC, Spellman SR. Recommendations for donor human leukocyte antigen assessment and matching for allogeneic stem cell transplantation: consensus opinion of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant. 2015 Jan;21(1):4-7. PMCID: PMC4272893
58. D'Souza A, Pasquini M, Spellecy R. Is 'informed consent' an 'understood consent' in hematopoietic cell transplantation? Bone Marrow Transplant. 2015 Jan;50(1):10-4. PMCID: PMC4320584
59. Appelbaum FR, Anasetti C, Antin JH, Atkins H, Davies S, Devine S, Giralt S, Heslop H, Laport G, Lee SJ, Logan B, Pasquini M, Pulsipher M, Stadtmauer E, Wingard JR, Horowitz MM. Blood and marrow transplant clinical trials network state of the Science Symposium 2014. Biol Blood Marrow Transplant. 2015 Feb;21(2):202-24. PMCID: PMC4426907
60. Sucheston-Campbell LE, Clay A, McCarthy PL, Zhu Q, Preus L, Pasquini M, Onel K, Hahn T. Identification and utilization of donor and recipient genetic variants to predict survival after HCT: are we ready for primetime? Curr Hematol Malig Rep. 2015 Mar;10(1):45-58. PMCID: PMC4352187
61. Hong S, Le-Rademacher J, Artz A, McCarthy PL, Logan BR, Pasquini MC. Comparison of non-myeloablative conditioning regimens for lymphoproliferative disorders. Bone Marrow Transplant. 2015 Mar;50(3):367-74. PMCID: PMC4351124
62. Gratwohl A, Pasquini MC, Aljurf M, Atsuta Y, Baldomero H, Foeken L, Gratwohl M, Bouzas LF, Confer D, Frauendorfer K, Gluckman E, Greinix H, Horowitz M, Iida M, Lipton J, Madrigal A, Mohty M, Noel L, Novitzky N, Nunez J, Oudshoorn M, Passweg J, van Rood J, Szer J, Blume K, Appelbaum FR, Kodera Y, Niederwieser D, Worldwide Network for Blood and Marrow Transplantation (WBMT). One million haemopoietic stem-cell transplants: a retrospective observational study. Lancet Haematol. 2015 Mar;2(3):e91-100.
63. Majhail NS, Giralt S, Bonagura A, Crawford S, Farnia S, Omel JL, Pasquini M, Saber W, LeMaistre CF. Guidelines for defining and implementing standard episode of care for hematopoietic stem cell transplantation within the context of clinical trials. Biol Blood Marrow Transplant. 2015 Apr;21(4):583-8.
64. MacMillan ML, Robin M, Harris AC, DeFor TE, Martin PJ, Alousi A, Ho VT, Bolaños-Meade J, Ferrara JL, Jones R, Arora M, Blazar BR, Holtan SG, Jacobsohn D, Pasquini M, Socie G, Antin JH, Levine JE, Weisdorf DJ. A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality. Biol Blood Marrow Transplant. 2015 Apr;21(4):761-7. PMCID: PMC4359643
65. Dhakal B, D'Souza A, Arce-Lara C, Pasquini M, Saber W, Falvo F, Esselman J, Zellner K, Fenske T, Hari PN, Hamadani M. Superior efficacy but higher cost of plerixafor and abbreviated-course G-CSF for mobilizing hematopoietic progenitor cells (HPC) in AL amyloidosis. Bone Marrow Transplant. 2015 Apr;50(4):610-2.
66. Chen YB, Lane AA, Logan B, Zhu X, Akpek G, Aljurf M, Artz A, Bredeson CN, Cooke KR, Ho VT, Lazarus HM, Olsson R, Saber W, McCarthy P, Pasquini MC. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015 Jun;21(6):1046-1053. PMCID: PMC4426014
67. Holter-Chakrabarty JL, Pierson N, Zhang MJ, Zhu X, Akpek G, Aljurf MD, Artz AS, Baron F, Bredeson CN, Dvorak CC, Epstein RB, Lazarus HM, Olsson RF, Selby GB, Williams KM, Cooke KR, Pasquini MC, McCarthy PL. The Sequence of Cyclophosphamide and Myeloablative Total Body Irradiation in Hematopoietic Cell Transplantation for Patients with Acute Leukemia. Biol Blood Marrow Transplant. 2015 Jul;21(7):1251-7. PMCID: PMC4465990
68. Graff TM, Singavi AK, Schmidt W, Eastwood D, Drobyski WR, Horowitz M, Palmer J, Pasquini M, Rizzo DJ, Saber W, Hari P, Fenske TS. Safety of outpatient autologous hematopoietic cell transplantation for multiple myeloma and lymphoma. Bone Marrow Transplant. 2015 Jul;50(7):947-53. PMCID: PMC4490016
69. Cornell RF, Zhong X, Arce-Lara C, Atallah E, Blust L, Drobyski WR, Fenske TS, Pasquini MC, Rizzo JD, Saber W, Hari PN. Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation. Bone Marrow Transplant. 2015 Jul;50(7):914-7.
70. Sorror ML, Logan BR, Zhu X, Rizzo JD, Cooke KR, McCarthy PL, Ho VT, Horowitz MM, Pasquini MC. Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study. Biol Blood Marrow Transplant. 2015 Aug;21(8):1479-87. PMCID: PMC4512746
71. Olsson RF, Logan BR, Chaudhury S, Zhu X, Akpek G, Bolwell BJ, Bredeson CN, Dvorak CC, Gupta V, Ho VT, Lazarus HM, Marks DI, Ringdén OT, Pasquini MC, Schriber JR, Cooke KR. Primary graft failure after myeloablative allogeneic hematopoietic cell transplantation for hematologic malignancies. Leukemia. 2015 Aug;29(8):1754-62. PMCID: PMC4527886
72. Hahn T, Sucheston-Campbell LE, Preus L, Zhu X, Hansen JA, Martin PJ, Yan L, Liu S, Spellman S, Tritchler D, Clay A, Onel K, Pasquini M, McCarthy PL. Establishment of Definitions and Review Process for Consistent Adjudication of Cause-specific Mortality after Allogeneic Unrelated-donor Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2015 Sep;21(9):1679-1686. PMCID: PMC4537799
73. Hussain AS, Hari P, Brazauskas R, Arce-Lara C, Pasquini M, Hamadani M, D'Souza A. Changes in cardiac biomarkers with bortezomib treatment in patients with advanced cardiac amyloidosis. Am J Hematol. 2015 Nov;90(11):E212-3. PMCID: PMC4618044
74. Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, Hari P, Lokhorst H, McCarthy P, Krishnan A, Sonneveld P, Goldschmidt H, Jagannath S, Barlogie B, Mateos M, Gimsing P, Sezer O, Mikhael J, Lu J, Dimopoulos M, Mazumder A, Palumbo A, Abonour R, Anderson K, Attal M, Blade J, Bird J, Cavo M, Comenzo R, de la Rubia J, Einsele H, Garcia-Sanz R, Hillengass J, Holstein S, Johnsen HE, Joshua D, Koehne G, Kumar S, Kyle R, Leleu X, Lonial S, Ludwig H, Nahi H, Nooka A, Orlowski R, Rajkumar V, Reiman A, Richardson P, Riva E, San Miguel J, Turreson I, Usmani S, Vesole D, Bensinger W, Qazilbash M, Efebera Y, Mohty M, Gasparreto C, Gajewski J, LeMaistre CF, Bredeson C, Moreau P, Pasquini M, Kroeger N, Stadtmauer E. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biol Blood Marrow Transplant. 2015 Dec;21(12):2039-2051. PMCID: PMC4757494
75. Dhakal B, D'Souza A, Pasquini M, Saber W, Fenske TS, Moss RB, Drobyski WR, Hari P, Abidi MZ. DAS181 Treatment of Severe Parainfluenza Virus 3 Pneumonia in Allogeneic Hematopoietic Stem Cell Transplant Recipients Requiring Mechanical Ventilation. Case Rep Med. 2016;2016:8503275. PMCID: PMC4749780
76. Yoshimi A, Baldomero H, Horowitz M, Szer J, Niederwieser D, Gratwohl A, Kodera Y, Worldwide Network of Blood and Marrow Transplantation (WBMT). Global Use of Peripheral Blood vs Bone Marrow as Source of Stem Cells for Allogeneic Transplantation in Patients With Bone Marrow Failure. JAMA. 2016 Jan 12;315(2):198-200.
77. Pasquini MC, Zhang MJ, Medeiros BC, Armand P, Hu ZH, Nishihori T, Aljurf MD, Akpek G, Cahn JY, Cairo MS, Cerny J, Copelan EA, Deol A, Freytes CO, Gale RP, Ganguly S, George B, Gupta V, Hale GA, Kamble RT, Klumpp TR, Lazarus HM, Luger SM, Liesveld JL, Litzow MR, Marks DI, Martino R, Norkin M, Olsson RF, Oran B, Pawarode A, Pulsipher MA, Ramanathan M, Reshef R, Saad AA, Saber W, Savani BN, Schouten HC, Ringdén O, Tallman MS, Uy GL, Wood WA Jr, Wirk B, Pérez WS, Batiwalla M, Weisdorf DJ. Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. Biol Blood Marrow Transplant. 2016 Feb;22(2):248-257. PMCID: PMC4716890
78. Dhakal B, Brazauskas R, Lara CA, Hari P, Pasquini M, D'Souza A. Monocyte recovery at day 100 is associated with improved survival in multiple myeloma patients who undergo allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2016 Feb;51(2):297-9. PMCID: PMC4956087
79. Kanda J, Brazauskas R, Hu ZH, Kuwatsuka Y, Nagafuji K, Kanamori H, Kanda Y, Miyamura K, Murata M, Fukuda T, Sakamaki H, Kimura F, Seo S, Aljurf M, Yoshimi A, Milone G, Wood WA, Ustun C, Hashimi S, Pasquini M, Bonfim C, Dalal J, Hahn T, Atsuta Y, Saber W. Graft-versus-Host Disease after HLA-Matched Sibling Bone Marrow or Peripheral Blood Stem Cell Transplantation: Comparison of North American Caucasian and Japanese Populations. Biol Blood Marrow Transplant. 2016 Apr;22(4):744-751. PMCID: PMC4801761
80. Hanif A, Hari PN, Atallah E, Carlson KS, Pasquini MC, Michaelis LC. Safety of ruxolitinib therapy prior to allogeneic hematopoietic stem-cell transplantation for myeloproliferative neoplasms. Bone Marrow Transplant. 2016 Apr;51(4):617-8.
81. Kumar R, Kimura F, Ahn KW, Hu ZH, Kuwatsuka Y, Klein JP, Pasquini M, Miyamura K, Kato K, Yoshimi A, Inamoto Y, Ichinohe T, Wood WA Jr, Wirk B, Seftel M, Rowlings P, Marks DI, Schultz KR, Gupta V, Dedeken L, George B, Cahn JY, Szer J, Lee JW, Ho AY, Fasth A, Hahn T, Khera N, Dalal J, Bonfim C, Aljurf M, Atsuta Y, Saber W. Comparing Outcomes with Bone Marrow or Peripheral Blood Stem Cells as Graft Source for Matched Sibling Transplants in Severe Aplastic Anemia across Different Economic Regions. Biol Blood Marrow Transplant. 2016 May;22(5):932-40. PMCID: PMC4826285
82. Niederwieser D, Baldomero H, Szer J, Gratwohl M, Aljurf M, Atsuta Y, Bouzas LF, Confer D, Greinix H, Horowitz M, Iida M, Lipton J, Mohty M, Novitzky N, Nunez J, Passweg J, Pasquini MC, Kodera Y, Apperley J, Seber A, Gratwohl A. Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey. Bone Marrow Transplant. 2016 Jun;51(6):778-85. PMCID: PMC4889523
83. D'Souza A, Pasquini M, Logan B, Giralt S, Krishnan A, Antin J, Howard A, Goodman S, Qazilbash M, Knust K, Sahebi F, Weisdorf D, Vesole D, Stadtmauer E, Maloney D, Hari P. Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study. Br J Haematol. 2017 Sep;178(5):816-819. PMCID: PMC5154782
84. Flowers CR, Costa LJ, Pasquini MC, Le-Rademacher J, Lill M, Shore TB, Vaughan W, Craig M, Freytes CO, Shea TC, Horwitz ME, Fay JW, Mineishi S, Rondelli D, Mason J, Braunschweig I, Ai W, Yeh RF, Rodriguez TE, Flinn I, Comeau T, Yeager AM, Pulsipher MA, Bence-Bruckler I, Laneuville P, Bierman P, Chen AI, Kato K, Wang Y, Xu C, Smith AJ, Waller EK. Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes. Biol Blood Marrow Transplant. 2016 Jul;22(7):1197-1205. PMCID: PMC4914052
85. Dhakal B, D'Souza A, Martens M, Kapke J, Harrington AM, Pasquini M, Saber W, Drobyski WR, Zhang MJ, Hamadani M, Hari PN. Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival. Clin Lymphoma Myeloma Leuk. 2016 Jul;16(7):379-86.
86. Gale RP, Seber A, Bonfim C, Pasquini M. Haematopoietic cell transplants in Latin America. Bone Marrow Transplant. 2016 Jul;51(7):898-905. PMCID: PMC4935585
87. Hicks LK, Rajasekhar A, Bering H, Carson KR, Kleinerman J, Kukreti V, Ma A, Mueller BU, O'Brien SH, Panepinto JA, Pasquini MC, Sarode R, Wood WA. Identifying existing Choosing Wisely recommendations of high relevance and importance to hematology. Am J Hematol. 2016 Aug;91(8):787-92.
88. Pasquini MC, Le-Rademacher J, Zhu X, Artz A, DiPersio J, Fernandez HF, Mineishi S, Kamishohara M, Mehta J, Nakamura Y, Ratanatharathorn V, Sobecks R, Burkart J, Bredeson C. Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies. Biol Blood Marrow Transplant. 2016 Aug;22(8):1424-1430. PMCID: PMC4949158
89. Dhakal B, Veltri LW, Fenske TS, Eastwood D, Craig MD, Cumpston A, Shillingburg A, Esselman J, Watkins K, Pasquini MC, D'Souza A, Hari P, Kanate AS, Hamadani M. Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2016 Oct;22(10):1773-1780.
90. Artz AS, Logan B, Zhu X, Akpek G, Bufarull RM, Gupta V, Lazarus HM, Litzow M, Loren A, Majhail NS, Maziarz RT, McCarthy P, Popat U, Saber W, Spellman S, Ringden O, Wickrema A, Pasquini MC, Cooke KR, from the Center for International Blood and Marrow Transplantation Research. The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes. Haematologica. 2016 Nov;101(11):1426-1433. PMCID: PMC5394859
91. Martin PJ, Fan W, Storer BE, Levine DM, Zhao LP, Warren EH, Flowers ME, Lee SJ, Carpenter PA, Boeckh M, Hingorani S, Yan L, Hu Q, Preus L, Liu S, Spellman S, Zhu X, Pasquini M, McCarthy P, Stram D, Sheng X, Pooler L, Haiman CA, Sucheston-Campbell L, Hahn T, Hansen JA. Replication of associations between genetic polymorphisms and chronic graft-versus-host disease. Blood. 2016 Nov 17;128(20):2450-2456. PMCID: PMC5114491
92. Raj RV, Hari P, Pasquini M, Epperla N, D'Souza A, Fenske T, Shaw BE, Rizzo JD, Drobyski W, Hamadani M. Impact of haploidentical hematopoietic cell transplantation conditioning intensity on the incidence and severity of post-transplantation viral infections. Bone Marrow Transplant. 2016 Dec;51(12):1602-1604.
93. Epperla N, Pasquini M, Pierce K, Drobyski WR, Rizzo JD, Horowitz MM, Saber W, Zellner K, Ramirez S, Bartz K, Raj RV, Hari PN, Hamadani M. Salvage haploidentical hematopoietic cell transplantation for graft rejection following a prior haploidentical allograft. Bone Marrow Transplant. 2017 Jan;52(1):147-150.
94. Dhakal B, Nelson A, Guru Murthy GS, Fraser R, Eastwood D, Hamadani M, Pasquini M, D'Souza A, Hari P. Autologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma: Effect of Age. Clin Lymphoma Myeloma Leuk. 2017 Mar;17(3):165-172.
95. Weil E, Zook F, Oxencis C, Canadeo A, Urmanski A, Waggoner M, Eastwood D, Pasquini M, Hamadani M, Hari P. Evaluation of the Pharmacokinetics and Efficacy of a Busulfan Test Dose in Adult Patients Undergoing Myeloablative Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2017 Jun;23(6):952-957.
96. Muraro PA, Pasquini M, Atkins HL, Bowen JD, Farge D, Fassas A, Freedman MS, Georges GE, Gualandi F, Hamerschlak N, Havrdova E, Kimiskidis VK, Kozak T, Mancardi GL, Massacesi L, Moraes DA, Nash RA, Pavletic S, Ouyang J, Rovira M, Saiz A, Simoes B, Trnený M, Zhu L, Badoglio M, Zhong X, Sormani MP, Saccardi R, Multiple Sclerosis–Autologous Hematopoietic Stem Cell Transplantation (MS-AHSCT) Long-term Outcomes Study Group. Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. JAMA Neurol. 2017 Apr 01;74(4):459-469. PMCID: PMC5744858
97. Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick ED, Fernandez HF, Alyea EP, Hamadani M, Bashey A, Giralt S, Geller NL, Leifer E, Le-Rademacher J, Mendizabal AM, Horowitz MM, Deeg HJ, Horwitz ME. Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. J Clin Oncol. 2017 Apr 10;35(11):1154-1161. PMCID: PMC5455603
98. Kanate AS, Hari PN, Pasquini MC, Visotcky A, Ahn KW, Boyd J, Guru Murthy GS, Rizzo JD, Saber W, Drobyski W, Michaelis L, Atallah E, Carlson KS, D'Souza A, Fenske TS, Cumpston A, Bunner P, Craig M, Horowitz MM, Hamadani M. Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation. Biol Blood Marrow Transplant. 2017 Aug;23(8):1295-1302.
99. Jaimovich G, Martinez Rolon J, Baldomero H, Rivas M, Hanesman I, Bouzas L, Bonfim C, Palma J, Kardus-Urueta A, Ubidia D, Bujan-Boza W, Gonzalez-Ramella O, Ruiz-Argüelles G, Gomez-Almaguer D, Espino G, Fanilla E, Gonzalez D, Carrasco A, Galeano S, Borelli G, Hernandez-Gimenez M, Pasquini M, Kodera Y, Gratwohl A, Gratwohl M, Nuñez J, Szer J, Gale RP, Niederwieser D, Seber A. Latin America: the next region for haematopoietic transplant progress. Bone Marrow Transplant. 2017 May;52(5):671-677.
100. Jaimovich G, Rolon JM, Baldomero H, Rivas M, Hanesman I, Bouzas L, Bonfim C, Palma J, Kardus-Urueta A, Ubidia D, Bujan-Boza W, Gonzalez-Ramella O, Ruiz-Argüelles G, Gomez-Almaguer D, Espino G, Fanilla E, Gonzalez D, Carrasco A, Galeano S, Borelli G, Hernandez-Gimenez M, Pasquini M, Kodera Y, Gratwohl A, Gratwohl M, Nuñez J, Szer J, Gale RP, Niederwieser D, Seber A. Latin America: the next region for haematopoietic transplant progress. Bone Marrow Transplant. 2017 May;52(5):798.
101. D'Souza A, Lee S, Zhu X, Pasquini M. Current Use and Trends in Hematopoietic Cell Transplantation in the United States. Biol Blood Marrow Transplant. 2017 Sep;23(9):1417-1421. PMCID: PMC5565685
102. Jerkins JH, Hamadani M, Zook F, Epperla N, Shaw BE, Saber W, Rizzo JD, Pasquini M, Chhabra S, Drobyski WR, Hari PN, Shah NN. Alpha-1-antitrypsin for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease. Am J Hematol. 2017 Oct;92(10):E610-E611.
103. Muffly L, Pasquini MC, Martens M, Brazauskas R, Zhu X, Adekola K, Aljurf M, Ballen KK, Bajel A, Baron F, Battiwalla M, Beitinjaneh A, Cahn JY, Carabasi M, Chen YB, Chhabra S, Ciurea S, Copelan E, D'Souza A, Edwards J, Foran J, Freytes CO, Fung HC, Gale RP, Giralt S, Hashmi SK, Hildebrandt GC, Ho V, Jakubowski A, Lazarus H, Luskin MR, Martino R, Maziarz R, McCarthy P, Nishihori T, Olin R, Olsson RF, Pawarode A, Peres E, Rezvani AR, Rizzieri D, Savani BN, Schouten HC, Sabloff M, Seftel M, Seo S, Sorror ML, Szer J, Wirk BM, Wood WA, Artz A. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood. 2017 Aug 31;130(9):1156-1164. PMCID: PMC5580273
104. D'Souza A, Zhang MJ, Huang J, Fei M, Pasquini M, Hamadani M, Hari P. Trends in pre- and post-transplant therapies with first autologous hematopoietic cell transplantation among patients with multiple myeloma in the United States, 2004-2014. Leukemia. 2017 Sep;31(9):1998-2000. PMCID: PMC5587375
105. Thompson J, Yin Z, D'Souza A, Fenske T, Hamadani M, Hari P, Rizzo JD, Pasquini M, Saber W, Shah N, Shaw BE, Shahir K, Banerjee A, Drobyski WR. Etanercept and Corticosteroid Therapy for the Treatment of Late-Onset Idiopathic Pneumonia Syndrome. Biol Blood Marrow Transplant. 2017 Nov;23(11):1955-1960.
106. Hashmi SK, Srivastava A, Rasheed W, Adil S, Wu T, Jagasia M, Nassar A, Hwang WYK, Hamidieh AA, Greinix HT, Pasquini MC, Apperley JF, Aljurf M. Cost and quality issues in establishing hematopoietic cell transplant program in developing countries. Hematol Oncol Stem Cell Ther. 2017 Dec;10(4):167-172.
107. Hammons L, Brazauskas R, Pasquini M, Hamadani M, Hari P, D'Souza A. Presence of fluorescent in situ hybridization abnormalities is associated with plasma cell burden in light chain amyloidosis. Hematol Oncol Stem Cell Ther. 2018 Jun;11(2):105-111.
108. Holstein SA, Jung SH, Richardson PG, Hofmeister CC, Hurd DD, Hassoun H, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, van Besien K, Gentile TG, Isola L, Maziarz RT, Bashey A, Landau H, Martin T, Qazilbash MH, Rodriguez C, McClune B, Schlossman RL, Smith SE, Hars V, Owzar K, Jiang C, Boyd M, Schultz C, Wilson M, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Linker C, Anderson KC, McCarthy PL. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol. 2017 Sep;4(9):e431-e442. PMCID: PMC5718627
109. Karaesmen E, Rizvi AA, Preus LM, McCarthy PL, Pasquini MC, Onel K, Zhu X, Spellman S, Haiman CA, Stram DO, Pooler L, Sheng X, Zhu Q, Yan L, Liu Q, Hu Q, Webb A, Brock G, Clay-Gilmour AI, Battaglia S, Tritchler D, Liu S, Hahn T, Sucheston-Campbell LE. Replication and validation of genetic polymorphisms associated with survival after allogeneic blood or marrow transplant. Blood. 2017 Sep 28;130(13):1585-1596. PMCID: PMC5620418
110. Scolding NJ, Pasquini M, Reingold SC, Cohen JA, International Conference on Cell-Based Therapies for Multiple Sclerosis, International Conference on Cell-Based Therapies for Multiple Sclerosis, International Conference on Cell-Based Therapies for Multiple Sclerosis. Cell-based therapeutic strategies for multiple sclerosis. Brain. 2017 Nov 01;140(11):2776-2796. PMCID: PMC5841198
111. Clay-Gilmour AI, Hahn T, Preus LM, Onel K, Skol A, Hungate E, Zhu Q, Haiman CA, Stram DO, Pooler L, Sheng X, Yan L, Liu Q, Hu Q, Liu S, Battaglia S, Zhu X, Block AW, Sait SNJ, Karaesmen E, Rizvi A, Weisdorf DJ, Ambrosone CB, Tritchler D, Ellinghaus E, Ellinghaus D, Stanulla M, Clavel J, Orsi L, Spellman S, Pasquini MC, McCarthy PL, Sucheston-Campbell LE. Genetic association with B-cell acute lymphoblastic leukemia in allogeneic transplant patients differs by age and sex. Blood Adv. 2017 Sep 12;1(20):1717-1728. PMCID: PMC5728332
112. Holstein SA, Avet-Loiseau H, Hahn T, Ho CM, Lohr JG, Munshi NC, Paiva B, Pasquini MC, Tario JD Jr, Usmani SZ, Wallace PK, Weisel K, McCarthy PL. BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee. Biol Blood Marrow Transplant. 2018 Apr;24(4):641-648. PMCID: PMC5902638
113. Pasquini MC, Logan B, Jones RJ, Alousi AM, Appelbaum FR, Bolaños-Meade J, Flowers MED, Giralt S, Horowitz MM, Jacobsohn D, Koreth J, Levine JE, Luznik L, Maziarz R, Mendizabal A, Pavletic S, Perales MA, Porter D, Reshef R, Weisdorf D, Antin JH. Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials. Biol Blood Marrow Transplant. 2018 Jun;24(6):1274-1280. PMCID: PMC5993573
114. Sureda A, Zhang MJ, Dreger P, Carreras J, Fenske T, Finel H, Schouten H, Montoto S, Robinson S, Smith SM, Boumedil A, Hamadani M, Pasquini MC. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. Cancer. 2018 Apr 15;124(8):1733-1742. PMCID: PMC5946312
115. Epperla N, Hamadani M, Ahn KW, He F, Kodali D, Kleman A, Hari PN, Pasquini M, Fenske TS, Craig MD, Kanate AS, Bachanova V. Survival of Lymphoma Patients Experiencing Relapse or Progression after an Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2018 May;24(5):983-988.
116. Drobyski WR, Szabo A, Zhu F, Keever-Taylor C, Hebert KM, Dunn R, Yim S, Johnson B, D'Souza A, Eapen M, Fenske TS, Hari P, Hamadani M, Horowitz MM, Rizzo JD, Saber W, Shah N, Shaw B, Pasquini M. Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-<i>versus</i>-host disease: low incidence of lower gastrointestinal tract disease. Haematologica. 2018 Apr;103(4):717-727. PMCID: PMC5865423
117. Zhu Q, Yan L, Liu Q, Zhang C, Wei L, Hu Q, Preus L, Clay-Gilmour AI, Onel K, Stram DO, Pooler L, Sheng X, Haiman CA, Zhu X, Spellman SR, Pasquini M, McCarthy PL, Liu S, Hahn T, Sucheston-Campbell LE. Exome chip analyses identify genes affecting mortality after HLA-matched unrelated-donor blood and marrow transplantation. Blood. 2018 May 31;131(22):2490-2499. PMCID: PMC5981168
118. Dhakal B, D'Souza A, Lakshman A, Hamadani M, Chhabra S, Thompson R, Shah N, Pasquini M, Hari P. Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2018 Aug;24(8):1610-1614.
119. D'Souza A, Flynn K, Chhabra S, Dhakal B, Hamadani M, Jacobsen K, Pasquini M, Weihrauch D, Hari P. Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis. Contemp Clin Trials Commun. 2017 Dec;8:33-38. PMCID: PMC5898504
120. Raj RV, Hamadani M, Szabo A, Pasquini MC, Shah NN, Drobyski WR, Shaw BE, Saber W, Rizzo JD, Jerkins J, Fenske TS, D'Souza A, Dhakal B, Zhang C, Konings S, Hari PN, Chhabra S. Peripheral Blood Grafts for T Cell-Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome. Biol Blood Marrow Transplant. 2018 Aug;24(8):1664-1670.
121. Badar T, Hari P, Chhabra S, Dhakal B, Drobyski WR, Fenske TS, Hamadani M, Pasquini M, Saber W, Shah NN, Shaw BE, D'Souza A. Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective. Bone Marrow Transplant. 2018 Sep;53(9):1210-1213.
122. Sullivan KM, Majhail NS, Bredeson C, Carpenter PA, Chatterjee S, Crofford LJ, Georges GE, Nash RA, Pasquini MC, Sarantopoulos S, Storek J, Savani B, St Clair EW. Systemic Sclerosis as an Indication for Autologous Hematopoietic Cell Transplantation: Position Statement from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2018 Oct;24(10):1961-1964. PMCID: PMC6239926
123. Strouse C, Zhang Y, Zhang MJ, DiGilio A, Pasquini M, Horowitz MM, Lee S, Ho V, Ramanathan M, Chinratanalab W, Loren A, Burns LJ, Artz A, Villa KF, Saber W. Risk Score for the Development of Veno-Occlusive Disease after Allogeneic Hematopoietic Cell Transplant. Biol Blood Marrow Transplant. 2018 Oct;24(10):2072-2080. PMCID: PMC6239945
124. Sureda A, Montoto S, Dreger P, Hamadani M, Pasquini MC. Reply to the persistent uncertainty of when to recommend allogeneic stem cell transplantation in follicular iymphoma. Cancer. 2018 Aug;124(16):3455-3456.
125. Harris AC, Boelens JJ, Ahn KW, Fei M, Abraham A, Artz A, Dvorak C, Frangoul H, Freytes C, Gale RP, Hong S, Lazarus HM, Loren A, Mineishi S, Nishihori T, O'Brien T, Williams K, Pasquini MC, Levine JE. Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine. Blood Adv. 2018 Jun 12;2(11):1198-1206. PMCID: PMC5998928
126. Baldomero H, Aljurf M, Zaidi SZA, Hashmi SK, Ghavamzadeh A, Elhaddad A, Hamladji RM, Ahmed P, Torjemane L, Abboud M, Tbakhi A, Khabori MA, El Quessar A, Bazuaye N, Bekadja MA, Adil S, Fahmy O, Ramzi M, Ibrahim A, Alseraihy A, Ben Abdejalil N, Sarhan M, Huneini MA, Mahmal L, ElSolh H, Hussain F, Nassar A, Al-Hashmi H, Hamidieh AA, Pasquini M, Kodera Y, Kröger N, Mohty M, Jaimovich G, Rolon JM, Paulson K, Greinix H, Weisdorf D, Horowitz M, Nunez J, Gratwohl A, Passweg J, Koh M, Szer J, Niederwieser D, Novitzky N, East-Mediterranean (EMBMT) and African (AfBMT) Blood and Marrow Transplantation Groups and the Worldwide Network for Blood and Marrow Transplantation (WBMT). Narrowing the gap for hematopoietic stem cell transplantation in the East-Mediterranean/African region: comparison with global HSCT indications and trends. Bone Marrow Transplant. 2019 Mar;54(3):402-417. PMCID: PMC6363888
127. Stadtmauer EA, Pasquini MC, Blackwell B, Hari P, Bashey A, Devine S, Efebera Y, Ganguly S, Gasparetto C, Geller N, Horowitz MM, Koreth J, Knust K, Landau H, Brunstein C, McCarthy P, Nelson C, Qazilbash MH, Shah N, Vesole DH, Vij R, Vogl DT, Giralt S, Somlo G, Krishnan A. Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial. J Clin Oncol. 2019 Mar 01;37(7):589-597. PMCID: PMC6553842
128. Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, Go WY, Eldjerou L, Gardner RA, Frey N, Curran KJ, Peggs K, Pasquini M, DiPersio JF, van den Brink MRM, Komanduri KV, Grupp SA, Neelapu SS. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638.
129. Guru Murthy GS, Hari PN, Szabo A, Pasquini M, Narra R, Khan M, Abedin S, Chhabra S, Dhakal B, D'Souza A, Drobyski WR, Rizzo JD, Runaas L, Shah NN, Shaw B, Saber W, Fenske T, Hamadani M. Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting. Biol Blood Marrow Transplant. 2019 Apr;25(4):827-833.
130. Thakar MS, Broglie L, Logan B, Artz A, Bunin N, Burroughs LM, Fretham C, Jacobsohn DA, Loren AW, Kurtzberg J, Martinez CA, Mineishi S, Nelson AS, Woolfrey A, Pasquini MC, Sorror ML. The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases. Blood. 2019 Feb 14;133(7):754-762. PMCID: PMC6376282
131. Brunstein CG, Pasquini MC, Kim S, Fei M, Adekola K, Ahmed I, Aljurf M, Agrawal V, Auletta JJ, Battiwalla M, Bejanyan N, Bubalo J, Cerny J, Chee L, Ciurea SO, Freytes C, Gadalla SM, Gale RP, Ganguly S, Hashmi SK, Hematti P, Hildebrandt G, Holmberg LA, Lahoud OB, Landau H, Lazarus HM, de Lima M, Mathews V, Maziarz R, Nishihori T, Norkin M, Olsson R, Reshef R, Rotz S, Savani B, Schouten HC, Seo S, Wirk BM, Yared J, Mineishi S, Rogosheske J, Perales MA. Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019 Mar;25(3):480-487. PMCID: PMC6445718
132. Holstein SA, Ye JC, Howard A, Bhutani M, Gormley N, Hahn T, Hillengass J, Krishnan A, Landgren CO, Munshi NC, Oliva S, Owen RG, Pasquini MC, Puig N, Weinhold N, Weisel K, McCarthy PL. Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biol Blood Marrow Transplant. 2019 Mar;25(3):e89-e97. PMCID: PMC6445685
133. Cohen JA, Baldassari LE, Atkins HL, Bowen JD, Bredeson C, Carpenter PA, Corboy JR, Freedman MS, Griffith LM, Lowsky R, Majhail NS, Muraro PA, Nash RA, Pasquini MC, Sarantopoulos S, Savani BN, Storek J, Sullivan KM, Georges GE. Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019 May;25(5):845-854.
134. Aljurf M, Weisdorf D, Alfraih F, Szer J, Müller C, Confer D, Hashmi S, Kröger N, Shaw BE, Greinix H, Kharfan-Dabaja MA, Foeken L, Seber A, Ahmed S, El-Jawahri A, Al-Awwami M, Atsuta Y, Pasquini M, Hanbali A, Alzahrani H, Okamoto S, Gluckman E, Mohty M, Kodera Y, Horowitz M, Niederwieser D, El Fakih R. "Worldwide Network for Blood & Marrow Transplantation (WBMT) special article, challenges facing emerging alternate donor registries". Bone Marrow Transplant. 2019 Aug;54(8):1179-1188. PMCID: PMC6760540
135. Bolaños-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, Alousi AM, Antin JH, Arai S, Bickett K, Chen YB, Damon LE, Efebera YA, Geller NL, Giralt SA, Hari P, Holtan SG, Horowitz MM, Jacobsohn DA, Jones RJ, Liesveld JL, Logan BR, MacMillan ML, Mielcarek M, Noel P, Pidala J, Porter DL, Pusic I, Sobecks R, Solomon SR, Weisdorf DJ, Wu J, Pasquini MC, Koreth J. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). Lancet Haematol. 2019 Mar;6(3):e132-e143. PMCID: PMC6503965
136. Tarsitani L, Ferracuti S, Carabellese F, Catanesi R, Biondi M, Quartesan R, Pasquini M, Mandarelli G. Brief Psychiatric Rating Scale-Expanded (BPRS-E) factor analysis in involuntarily hospitalized psychiatric patients. Psychiatry Res. 2019 Sep;279:380-381.
137. D'Souza A, Hari P, Pasquini M, Braun T, Johnson B, Lundy S, Couriel D, Hamadani M, Magenau J, Dhakal B, Shah NN, Riwes M, Parkin B, Reddy P, Pawarode A. A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant. 2019 Aug;25(8):1492-1497.
138. Severino P, Mariani MV, Maraone A, Piro A, Ceccacci A, Tarsitani L, Maestrini V, Mancone M, Lavalle C, Pasquini M, Fedele F. Triggers for Atrial Fibrillation: The Role of Anxiety. Cardiol Res Pract. 2019;2019:1208505. PMCID: PMC6398072
139. Parikh SH, Satwani P, Ahn KW, Sahr NA, Fretham C, Abraham AA, Agrawal V, Auletta JJ, Abdel-Azim H, Copelan E, Diaz MA, Dvorak CC, Frangoul HA, Freytes CO, Gadalla SM, Gale RP, George B, Gergis U, Hashmi S, Hematti P, Hildebrandt GC, Keating AK, Lazarus HM, Myers KC, Olsson RF, Prestidge T, Rotz SJ, Savani BN, Shereck EB, Williams KM, Wirk B, Pasquini MC, Loren AW. Survival Trends in Infants Undergoing Allogeneic Hematopoietic Cell Transplant. JAMA Pediatr. 2019 May 01;173(5):e190081. PMCID: PMC6503511
140. Kanate AS, Szabo A, Raj RV, Bower K, Grulke R, Shah N, Ross KG, Cumpston A, Craig M, Pasquini MC, Shah N, Hari P, Hamadani M, Chhabra S. Comparison of Graft Acquisition and Early Direct Charges of Haploidentical Related Donor Transplantation versus Umbilical Cord Blood Transplantation. Biol Blood Marrow Transplant. 2019 Jul;25(7):1456-1464.
141. McCune JS, Wang T, Bo-Subait K, Aljurf M, Beitinjaneh A, Bubalo J, Cahn JY, Cerny J, Chhabra S, Cumpston A, Dupuis LL, Lazarus HM, Marks DI, Maziarz RT, Norkin M, Prestidge T, Mineishi S, Krem MM, Pasquini M, Martin PJ. Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning. Biol Blood Marrow Transplant. 2019 Jul;25(7):1424-1431. PMCID: PMC6615968
142. Duchaussoy T, Budzik JF, Norberciak L, Colas L, Pasquini M, Verclytte S. Synthetic T2 mapping is correlated with time from stroke onset: a future tool in wake-up stroke management? Eur Radiol. 2019 Dec;29(12):7019-7026.
143. Pasquini MC, Srivastava A, Ahmed SO, Aljurf M, Atsuta Y, Doleysh C, Galeano S, Gluckman E, Greinix H, Hale GA, Hari P, Hashmi SK, Kamani N, Laughlin MJ, Niederwieser D, Seber A, Szer J, Snowden JA, Van Biesen K, Watry P, Weisdorf DJ, Apperley J. Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Cell Transplantation Program, Part I: Minimum Requirements and Beyond. Biol Blood Marrow Transplant. 2019 Dec;25(12):2322-2329.
144. McCune JS, Quinones CM, Ritchie J, Carpenter PA, van Maarseveen E, Yeh RF, Anasetti C, Boelens JJ, Hamerschlak N, Hassan M, Kang HJ, Kanda Y, Paci A, Perales MA, Shaw PJ, Seewaldt VL, Savani BN, Hsieh A, Poon B, Mohty M, Pulsipher MA, Pasquini M, Dupuis LL. Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement. Biol Blood Marrow Transplant. 2019 Sep;25(9):1890-1897. PMCID: PMC6755045
145. Aljurf M, Weisdorf D, Hashmi S, Nassar A, Gluckman E, Mohty M, Rizzo D, Pasquini M, Hamadani M, Saber W, Hari P, Kharfan-Dabaja M, Majhail N, Gerges U, Hamidieh AA, Hussain F, Elhaddad A, Mahmoud HK, Tbakhi A, Othman TB, Hamladji RM, Bekadja MA, Ahmed P, Bazarbachi A, Adil S, Alkindi S, Ladeb S, Dennison D, Patel M, Lu P, Quessar AE, Okamoto S, Atsuta Y, Alhejazi A, Ayas MF, Ahmed SO, Novitzky N, Srivastava A, Seber A, Solh HE, Ghavamzadeh A, Confer D, Kodera Y, Hildegard G, Szer J, Horowitz MM, Niederwieser D. Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Stem Cell Transplantation Program in Countries with Limited Resources, Part II: Clinical, Technical, and Socioeconomic Considerations. Biol Blood Marrow Transplant. 2019 Dec;25(12):2330-2337.
146. Abedin S, McKenna E, Chhabra S, Pasquini M, Shah NN, Jerkins J, Baim A, Runaas L, Longo W, Drobyski W, Hari PN, Hamadani M. Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019 Aug;25(8):1689-1694.
147. Broglie L, Fretham C, Al-Seraihy A, George B, Kurtzberg J, Loren A, MacMillan M, Martinez C, Davies SM, Pasquini MC. Pulmonary Complications in Pediatric and Adolescent Patients Following Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019 Oct;25(10):2024-2030. PMCID: PMC7262781
148. Dhakal B, D'Souza A, Hamadani M, Arce-Lara C, Schroeder K, Chhabra S, Shah NN, Gauger K, Keaton T, Pasquini M, Hari P. Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma. Blood Cancer J. 2019 Jul 29;9(8):56. PMCID: PMC6663939
149. D'Souza A, Hari P, Pasquini M, Jacobsen K, Flynn KE. Baseline patient-reported outcomes in light-chain amyloidosis patients enrolled on an interventional clinical trial. Amyloid. 2019;26(sup1):87-88. PMCID: PMC7108667
150. Dhakal B, Giri S, Levin A, Rein L, Fenske TS, Chhabra S, Shah NN, Szabo A, D'Souza A, Pasquini M, Hari P, Hamadani M. Factors Associated With Unplanned 30-Day Readmissions After Hematopoietic Cell Transplantation Among US Hospitals. JAMA Netw Open. 2019 Jul 03;2(7):e196476.
151. Nishihori T, Kharfan-Dabaja MA, Ochoa-Bayona JL, Bazarbachi A, Pasquini M, Alsina M. Role of reduced intensity conditioning in allogeneic hematopoietic cell transplantation for patients with multiple myeloma Hematology/ Oncology and Stem Cell Therapy. 2011;4(1):1-9.
152. Tang H, Hahn T, Karaesmen E, Rizvi AA, Wang J, Paczesny S, Wang T, Preus L, Zhu Q, Wang Y, Haiman CA, Stram D, Pooler L, Sheng X, Van Den Berg D, Brock G, Webb A, Pasquini MC, McCarthy PL, Spellman SR, Sucheston-Campbell LE. Validation of genetic associations with acute GVHD and nonrelapse mortality in DISCOVeRY-BMT. Blood Adv. 2019 Aug 13;3(15):2337-2341. PMCID: PMC6693017
153. Solomon SR, St Martin A, Shah NN, Fatobene G, Al Malki MM, Ballen KK, Bashey A, Bejanyan N, Bolaños Meade J, Brunstein CG, DeFilipp Z, Champlin RE, Fuchs EJ, Hamadani M, Hematti P, Kanakry CG, McGuirk JP, McNiece IK, Ciurea SO, Pasquini MC, Rocha V, Romee R, Patel SS, Vasu S, Waller EK, Wingard JR, Zhang MJ, Eapen M. Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy. Blood Adv. 2019 Oct 08;3(19):2836-2844. PMCID: PMC6784523
154. Sabloff M, Chhabra S, Wang T, Fretham C, Kekre N, Abraham A, Adekola K, Auletta JJ, Barker C, Beitinjaneh AM, Bredeson C, Cahn JY, Diaz MA, Freytes C, Gale RP, Ganguly S, Gergis U, Guinan E, Hamilton BK, Hashmi S, Hematti P, Hildebrandt G, Holmberg L, Hong S, Lazarus HM, Martino R, Muffly L, Nishihori T, Perales MA, Yared J, Mineishi S, Stadtmauer EA, Pasquini MC, Loren AW. Comparison of High Doses of Total Body Irradiation in Myeloablative Conditioning before Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019 Dec;25(12):2398-2407. PMCID: PMC7304318
155. Aljurf M, Weisdorf D, Hashmi SK, Nassar A, Gluckman E, Mohty M, Rizzo D, Pasquini M, Hamadani M, Saber W, Hari P, Kharfan-Dabaja M, Majhail N, Gerges U, Hamidieh AA, Hussain F, Elhaddad A, Mahmoud HK, Tbakhi A, Othman TB, Hamladji RM, Bekadja MA, Ahmed P, Bazarbachi A, Adil S, Alkindi S, Ladeb S, Dennison D, Patel M, Lu P, Quessar AE, Okamoto S, Atsuta Y, Alhejazi A, Ayas M, Ahmed SO, Novitzky N, Srivastava A, Seber A, Elsolh H, Ghavamzadeh A, Confer D, Kodera Y, Greinix H, Szer J, Horowitz M, Niederwieser D. Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic stem cell transplantation program in countries with limited resources (Part II): Clinical, technical and socio-economic considerations. Hematol Oncol Stem Cell Ther. 2020 Mar;13(1):7-16.
156. Pasquini MC, Srivastava A, Ahmed SO, Aljurf M, Atsuta Y, Doleysh C, Galeano S, Gluckman E, Greinix H, Hale G, Hari P, Hashmi SK, Kamani N, Laughlin MJ, Niederwieser D, Seber A, Szer J, Snowden JA, Van Biesen K, Watry P, Weisdorf DJ, Apperley J. Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic cell transplantation program (Part I): Minimum requirements and beyond. Hematol Oncol Stem Cell Ther. 2020 Sep;13(3):131-142. PMCID: PMC7125509
157. Karaesmen E, Hahn T, Dile AJ, Rizvi AA, Wang J, Wang T, Haagenson MD, Preus L, Zhu Q, Liu Q, Yan L, Liu S, Haiman CA, Stram D, Pooler L, Sheng X, Van Den Berg D, Brock G, Webb A, McCarthy PL, Pasquini MC, Spellman SR, Lee SJ, Paczesny S, Sucheston-Campbell LE. Multiple functional variants in the <i>IL1RL1</i> region are pretransplant markers for risk of GVHD and infection deaths. Blood Adv. 2019 Aug 27;3(16):2512-2524. PMCID: PMC6712530
158. Muhsen IN, Hashmi SK, Niederwieser D, Kroeger N, Agrawal S, Pasquini MC, Atsuta Y, Ballen KK, Seber A, Saber W, Kharfan-Dabaja MA, Rasheed W, Okamoto S, Khera N, Wood WA, Koh MBC, Greinix H, Kodera Y, Szer J, Horowitz MM, Weisdorf D, Aljurf M. Correction: Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries. Bone Marrow Transplant. 2020 Apr;55(4):837.
159. Zinter MS, Logan BR, Fretham C, Sapru A, Abraham A, Aljurf MD, Arnold SD, Artz A, Auletta JJ, Chhabra S, Copelan E, Duncan C, Gale RP, Guinan E, Hematti P, Keating AK, Marks DI, Olsson R, Savani BN, Ustun C, Williams KM, Pasquini MC, Dvorak CC. Comprehensive Prognostication in Critically Ill Pediatric Hematopoietic Cell Transplant Patients: Results from Merging the Center for International Blood and Marrow Transplant Research (CIBMTR) and Virtual Pediatric Systems (VPS) Registries. Biol Blood Marrow Transplant. 2020 Feb;26(2):333-342. PMCID: PMC6943183
160. Holstein SA, Al-Kadhimi Z, Costa LJ, Hahn T, Hari P, Hillengass J, Jacob A, Munshi NC, Oliva S, Pasquini MC, Shi Q, Stadtmauer EA, Waldvogel SL, McCarthy PL. Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biol Blood Marrow Transplant. 2020 Jan;26(1):e7-e15. PMCID: PMC6942175
161. Muhsen IN, Hashmi SK, Niederwieser D, Kroeger N, Agrawal S, Pasquini MC, Atsuta Y, Ballen KK, Seber A, Saber W, Kharfan-Dabaja MA, Rasheed W, Okamoto S, Khera N, Wood WA, Koh MBC, Greinix H, Kodera Y, Szer J, Horowitz MM, Weisdorf D, Aljurf M. Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries. Bone Marrow Transplant. 2020 Apr;55(4):698-707.
162. Dreger P, Fenske TS, Montoto S, Pasquini MC, Sureda A, Hamadani M, European Society for Blood and Marrow Transplantation (EBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR). Cellular Immunotherapy for Refractory Diffuse Large B Cell Lymphoma in the Chimeric Antigen Receptor-Engineered T Cell Era: Still a Role for Allogeneic Transplantation? Biol Blood Marrow Transplant. 2020 Apr;26(4):e77-e85. PMCID: PMC7207150
163. Hourigan CS, Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, Li Y, Licon A, Alyea EP, Bashey A, Deeg HJ, Devine SM, Fernandez HF, Giralt S, Hamadani M, Howard A, Maziarz RT, Porter DL, Scott BL, Warlick ED, Pasquini MC, Horwitz ME. Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease. J Clin Oncol. 2020 Apr 20;38(12):1273-1283. PMCID: PMC7164487
164. Giralt S, Costa LJ, Maloney D, Krishnan A, Fei M, Antin JH, Brunstein C, Geller N, Goodman S, Hari P, Logan B, Lowsky R, Qazilbash MH, Sahebi F, Somlo G, Rowley S, Vogl DT, Vesole DH, Pasquini M, Stadtmauer E. Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial. Biol Blood Marrow Transplant. 2020 Apr;26(4):798-804. PMCID: PMC7198329
165. Chhabra S, Narra RK, Wu R, Szabo A, George G, Michaelis LC, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Pasquini MC, Rizzo RD, Saber W, Shah NN, Shaw BE, Hamadani M, Hari PN. Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes. Biol Blood Marrow Transplant. 2020 May;26(5):893-901.
166. Costa LJ, Iacobelli S, Pasquini MC, Modi R, Giaccone L, Blade J, Schonland S, Evangelista A, Perez-Simon JA, Hari P, Brown EE, Giralt SA, Patriarca F, Stadtmauer EA, Rosinol L, Krishnan AY, Gahrton G, Bruno B. Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation. Bone Marrow Transplant. 2020 Sep;55(9):1810-1816. PMCID: PMC7483973
167. Rashidi A, Meybodi MA, Cao W, Chu H, Warlick ED, Devine S, Pasquini MC, Weisdorf DJ, Hamadani M. Myeloablative versus Reduced-Intensity Hematopoietic Cell Transplantation in Myelodysplastic Syndromes: Systematic Review and Meta-analysis. Biol Blood Marrow Transplant. 2020 Jun;26(6):e138-e141.
168. Chhabra S, Szabo A, Glisch C, George G, Narra RK, Harrington A, Jerkins JH, D'Souza A, Dhakal B, Pasquini MC, Hamadani M, Hari PN. Relapse after Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma: Survival Outcomes and Factors Influencing Them. Biol Blood Marrow Transplant. 2020 Jul;26(7):1288-1297.
169. Epperla N, Li A, Logan B, Fretham C, Chhabra S, Aljurf M, Chee L, Copelan E, Freytes CO, Hematti P, Lazarus HM, Litzow M, Nishihori T, Olsson RF, Prestidge T, Saber W, Wirk B, Yared JA, Loren A, Pasquini M. Incidence, Risk Factors for and Outcomes of Transplant-Associated Thrombotic Microangiopathy. Br J Haematol. 2020 Jun;189(6):1171-1181. PMCID: PMC7726817
170. Knight JM, Rizzo JD, Hari P, Pasquini MC, Giles KE, D'Souza A, Logan BR, Hamadani M, Chhabra S, Dhakal B, Shah N, Sriram D, Horowitz MM, Cole SW. Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial. Blood Adv. 2020 Feb 11;4(3):467-476. PMCID: PMC7013267
171. D'Souza A, Szabo A, Flynn KE, Dhakal B, Chhabra S, Pasquini MC, Weihrauch D, Hari PN. Adjuvant doxycycline to enhance anti-amyloid effects: Results from the dual phase 2 trial EClinicalMedicine. June 2020;23.
172. D'Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, Devine S, Eapen M, Hamadani M, Hari P, Pasquini MC, Perez W, Phelan RA, Riches ML, Rizzo JD, Saber W, Shaw BE, Spellman SR, Steinert P, Weisdorf DJ, Horowitz MM. Current Use of and Trends in Hematopoietic Cell Transplantation in the United States. Biol Blood Marrow Transplant. 2020 Aug;26(8):e177-e182. PMCID: PMC7404814
173. Eapen M, Zhang MJ, Tang XY, Lee SJ, Fei MW, Wang HL, Hebert KM, Arora M, Chhabra S, Devine SM, Hamadani M, D'Souza A, Pasquini MC, Phelan R, Rizzo JD, Saber W, Shaw BE, Weisdorf DJ, Horowitz MM. Hematopoietic Cell Transplantation with Cryopreserved Grafts for Severe Aplastic Anemia. Biol Blood Marrow Transplant. 2020 Jul;26(7):e161-e166. PMCID: PMC7206419
174. Abid MB, Hamadani M, Szabo A, Hari PN, Graham MB, Frank MO, Collier WS, Abedin S, Jerkins JH, Pasquini MC, Runaas L, Shah NN, Chhabra S. Severity of Cytokine Release Syndrome and Its Association with Infections after T Cell-Replete Haploidentical Related Donor Transplantation. Biol Blood Marrow Transplant. 2020 Sep;26(9):1670-1678.
175. Annapragada A, Sikora A, Bollard C, Conejo-Garcia J, Cruz CR, Demehri S, Demetriou M, Demirdjian L, Fong L, Horowitz M, Hutson A, Kadash-Edmondson K, Kufe D, Lipkin S, Liu S, McCarthy C, Morgan M, Morris Z, Pan Y, Pasquini M, Schoenberger S, Van Allen E, Vilar E, Xing Y, Zha W, IOTN Consortium, Odunsi A. Cancer Moonshot Immuno-Oncology Translational Network (IOTN): accelerating the clinical translation of basic discoveries for improving immunotherapy and immunoprevention of cancer. J Immunother Cancer. 2020 Jun;8(1). PMCID: PMC7304845
176. D'Souza A, Szabo A, Flynn KE, Dhakal B, Chhabra S, Pasquini MC, Weihrauch D, Hari PN. Adjuvant doxycycline to enhance anti-amyloid effects: Results from the dual phase 2 trial. EClinicalMedicine. 2020 Jun;23:100361. PMCID: PMC7280748
177. Frigault MJ, Nikiforow S, Mansour MK, Hu ZH, Horowitz MM, Riches ML, Hematti P, Turtle CJ, Zhang MJ, Perales MA, Pasquini MC. Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19? Blood. 2020 Jul 02;136(1):137-139. PMCID: PMC7332891
178. Holstein SA, Howard A, Avigan D, Bhutani M, Cohen AD, Costa LJ, Dhodapkar MV, Gay F, Gormley N, Green DJ, Hillengass J, Korde N, Li Z, Mailankody S, Neri P, Parekh S, Pasquini MC, Puig N, Roodman GD, Samur MK, Shah N, Shah UA, Shi Q, Spencer A, Suman VJ, Usmani SZ, McCarthy PL. Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biol Blood Marrow Transplant. 2020 Oct;26(10):e247-e255. PMCID: PMC7529908
179. Olin RL, Fretham C, Pasquini MC, Arora M, Bhatt VR, Derman B, Giralt SA, Huang LW, Koll T, Lee SM, Lin RJ, Pang L, Popat UR, Weisdorf DJ, Artz A. Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes. Blood Adv. 2020 Jun 23;4(12):2810-2820. PMCID: PMC7322958
180. Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Douglas Rizzo J, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M. Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2020 Oct;26(10):1876-1885. PMCID: PMC7571859
181. Costa LJ, Derman BA, Bal S, Sidana S, Chhabra S, Silbermann R, Ye JC, Cook G, Cornell RF, Holstein SA, Shi Q, Omel J, Callander NS, Chng WJ, Hungria V, Maiolino A, Stadtmauer E, Giralt S, Pasquini M, Jakubowiak AJ, Morgan GJ, Krishnan A, Jackson GH, Mohty M, Mateos MV, Dimopoulos MA, Facon T, Spencer A, Miguel JS, Hari P, Usmani SZ, Manier S, McCarthy P, Kumar S, Gay F, Paiva B. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia. 2021 Jan;35(1):18-30.
182. Monahan K, Kleman A, Thapa B, Szabo A, D'Souza A, Dhakal B, Jerkins JH, Pasquini MC, Hamadani M, Hari PN, Chhabra S. Propylene Glycol-Free Melphalan versus PG-Melphalan as Conditioning for Autologous Hematopoietic Cell Transplantation for Myeloma. Biol Blood Marrow Transplant. 2020 Dec;26(12):2229-2236.
183. Cowan AJ, Baldomero H, Atsuta Y, Mikhael J, Aljurf M, Seber A, Greinix H, Koh M, Worel N, Libby EN, Pasquini M, Galeano S, Saber W, Iida M, Jaimovich G, Rolon JM, Kodera Y, Benakli M, Nosa BG, Elhaddad A, Szer J, Passweg J, Kroeger N, Weisdorf D, Niederwieser D. The Global State of Hematopoietic Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation Database and the Global Burden of Disease Study. Biol Blood Marrow Transplant. 2020 Dec;26(12):2372-2377. PMCID: PMC7767639
184. Algwaiz G, Aljurf M, Koh M, Horowitz MM, Ljungman P, Weisdorf D, Saber W, Kodera Y, Szer J, Jawdat D, Wood WA, Brazauskas R, Lehmann L, Pasquini MC, Seber A, Lu PH, Atsuta Y, Riches M, Perales MA, Worel N, Okamoto S, Srivastava A, Chemaly RF, Cordonnier C, Dandoy CE, Wingard JR, Kharfan-Dabaja MA, Hamadani M, Majhail NS, Waghmare AA, Chao N, Kröger N, Shaw B, Mohty M, Niederwieser D, Greinix H, Hashmi SK, WBMT and the CIBMTR Health Services and International Studies Committee. Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee. Biol Blood Marrow Transplant. 2020 Dec;26(12):2181-2189. PMCID: PMC7380217
185. Chhabra S, Thapa B, Szabo A, Konings S, D'Souza A, Dhakal B, Jerkins JH, Pasquini MC, Johnson BD, Hari PN, Hamadani M. Utilization and Cost Implications of Hematopoietic Progenitor Cells Stored for a Future Salvage Autologous Transplantation or Stem Cell Boost in Myeloma Patients. Biol Blood Marrow Transplant. 2020 Nov;26(11):2011-2017.
186. van Doesum J, Chinea A, Pagliaro M, Pasquini MC, van Meerten T, Bakker M, Ammatuna E. Clinical characteristics and outcome of SARS-CoV-2-infected patients with haematological diseases: a retrospective case study in four hospitals in Italy, Spain and the Netherlands. Leukemia. 2020 Sep;34(9):2536-2538. PMCID: PMC7341026
187. Pasquini MC, Hu ZH, Curran K, Laetsch T, Locke F, Rouce R, Pulsipher MA, Phillips CL, Keating A, Frigault MJ, Salzberg D, Jaglowski S, Sasine JP, Rosenthal J, Ghosh M, Landsburg D, Margossian S, Martin PL, Kamdar MK, Hematti P, Nikiforow S, Turtle C, Perales MA, Steinert P, Horowitz MM, Moskop A, Pacaud L, Yi L, Chawla R, Bleickardt E, Grupp S. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020 Nov 10;4(21):5414-5424. PMCID: PMC7656920
188. Shalabi H, Gust J, Taraseviciute A, Wolters PL, Leahy AB, Sandi C, Laetsch TW, Wiener L, Gardner RA, Nussenblatt V, Hill JA, Curran KJ, Olson TS, Annesley C, Wang HW, Khan J, Pasquini MC, Duncan CN, Grupp SA, Pulsipher MA, Shah NN. Beyond the storm - subacute toxicities and late effects in children receiving CAR T cells. Nat Rev Clin Oncol. 2021 Jun;18(6):363-378. PMCID: PMC8335746
189. Knight JM, Costanzo ES, Singh S, Yin Z, Szabo A, Pawar DS, Hillard CJ, Rizzo JD, D'Souza A, Pasquini M, Coe CL, Irwin MR, Raison CL, Drobyski WR. The IL-6 antagonist tocilizumab is associated with worse depression and related symptoms in the medically ill. Transl Psychiatry. 2021 Jan 18;11(1):58. PMCID: PMC7812704
190. Watkins B, Qayed M, McCracken C, Bratrude B, Betz K, Suessmuth Y, Yu A, Sinclair S, Furlan S, Bosinger S, Tkachev V, Rhodes J, Tumlin AG, Narayan A, Cribbin K, Gillespie S, Gooley TA, Pasquini MC, Hebert K, Kapoor U, Rogatko A, Tighiouart M, Kim S, Bresee C, Choi SW, Davis J, Duncan C, Giller R, Grimley M, Harris AC, Jacobsohn D, Lalefar N, Norkin M, Farhadfar N, Pulsipher MA, Shenoy S, Petrovic A, Schultz KR, Yanik GA, Waller EK, Levine JE, Ferrara JL, Blazar BR, Langston A, Horan JT, Kean LS. Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD. J Clin Oncol. 2021 Jun 10;39(17):1865-1877. PMCID: PMC8260909
191. Wang Y, Zhou W, Wang J, Karaesmen E, Tang H, McCarthy PL, Pasquini MC, Wang Y, McReynolds LJ, Katki HA, Machiela MJ, Yeager M, Pooler L, Sheng X, Haiman CA, Van Den Berg D, Spellman SR, Wang T, Kuxhausen M, Chanock SJ, Lee SJ, Clay-Gilmour AI, Hahn TE, Gadalla SM, Sucheston-Campbell LE. Pre-HCT mosaicism increases relapse risk and lowers survival in acute lymphoblastic leukemia patients post-unrelated HCT Blood Advances. 12 January 2021;5(1):66-70.
192. Farhadfar N, Dias A, Wang T, Fretham C, Chhabra S, Murthy HS, Broglie L, D'Souza A, Gadalla SM, Gale RP, Hashmi S, Al-Homsi AS, Hildebrandt GC, Hematti P, Rizzieri D, Chee L, Lazarus HM, Bredeson C, Jaimes EA, Beitinjaneh A, Bashey A, Prestidge T, Krem MM, Marks DI, Benoit S, Yared JA, Nishihori T, Olsson RF, Freytes CO, Stadtmauer E, Savani BN, Sorror ML, Ganguly S, Wingard JR, Pasquini M. Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2021 May;27(5):410-422. PMCID: PMC8168834
193. Wang Y, Zhou W, Wang J, Karaesmen E, Tang H, McCarthy PL, Pasquini MC, Wang Y, McReynolds LJ, Katki HA, Machiela MJ, Yeager M, Pooler L, Sheng X, Haiman CA, Van Den Berg D, Spellman SR, Wang T, Kuxhausen M, Chanock SJ, Lee SJ, Clay-Gilmour AI, Hahn TE, Gadalla SM, Sucheston-Campbell LE. Pre-HCT mosaicism increases relapse risk and lowers survival in acute lymphoblastic leukemia patients post-unrelated HCT. Blood Adv. 2021 Jan 12;5(1):66-70. PMCID: PMC7805319
194. Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Rizzo JD, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M. Corrigendum to ‘Ixazomib for chronic Graft-Versus-Host Disease prophylaxis following allogeneic hematopoietic cell transplantation’ [Biology of Blood and Marrow Transplantation 26/10 (2020) 1876-1885] (Biology of Blood and Marrow Transplantation (2020) 26/10(1876-1885) (S1083879120304146), (10.1016/j.bbmt.2020.07.005)) Transplantation and Cellular Therapy. 2021.
195. Scott BL, Pasquini MC, Fei M, Fraser R, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick E, Fernandez HF, Soiffer RJ, Alyea E, Hamadani M, Bashey A, Giralt S, Geller NL, Leifer E, Hourigan CS, Gui G, Mendizabal A, Horowitz MM, Deeg HJ, Horwitz ME. Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial. Transplant Cell Ther. 2021 Jun;27(6):483.e1-483.e6. PMCID: PMC8217373
196. Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, Li Y, Licon A, Alyea EP, Bashey A, Devine SM, Fernandez HF, Giralt S, Hamadani M, Howard A, Maziarz RT, Porter DL, Warlick ED, Pasquini MC, Scott BL, Horwitz ME, Deeg HJ, Hourigan CS. Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic Syndrome. JCO Precis Oncol. 2021;5. PMCID: PMC8140814
197. D'Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, Devine S, Eapen M, Hamadani M, Hari P, Pasquini MC, Perez W, Phelan RA, Riches ML, Rizzo JD, Saber W, Shaw BE, Spellman SR, Steinert P, Weisdorf DJ, Horowitz MM. Corrigendum to ‘Current Use and Trends in Hematopoietic Cell Transplantation in the United States’ [Transplantation and Cellular Therapy 26/8 (2020) e177-e182] (Transplantation and Cellular Therapy (2020) 26/8(e177-e182) (S1083879120302251), (10.1016/j.bbmt.2020.04.013)) Transplantation and Cellular Therapy. 2021.
198. Ciurea SO, Kongtim P, Soebbing D, Trikha P, Behbehani G, Rondon G, Olson A, Bashir Q, Gulbis AM, Indreshpal K, Rezvani K, Shpall EJ, Bassett R, Cao K, Martin AS, Devine S, Horowitz M, Pasquini M, Lee DA, Champlin RE. Decrease post-transplant relapse using donor-derived expanded NK-cells Leukemia. 2021.
199. Paczesny S, Pasquini MC, Pavletic SZ, Agarwal A, Spellman S, Kean L, Bernatchez C, Gust J, Staedtke V, Perales MA. Blueprint for the discovery of biomarkers of toxicity and efficacy for CAR T cells and T-cell engagers. Blood Adv. 2021 Jun 08;5(11):2519-2522. PMCID: PMC8238483
200. Holstein SA, Bahlis N, Bergsagel PL, Bhutani M, Bolli N, Brownstein C, Demolis P, Foureau D, Gay F, Ghobrial IM, Gormley N, Hillengass J, Kaiser M, Maus MV, Melenhorst JJ, Merz M, Dwyer MO, Paiva B, Pasquini MC, Shah N, Wong SW, Usmani SZ, McCarthy PL. The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma. Transplant Cell Ther. 2021 Oct;27(10):807-816. PMCID: PMC8478786
201. Wang Y, Zhou W, McReynolds LJ, Katki HA, Griffiths EA, Thota S, Machiela MJ, Yeager M, McCarthy P, Pasquini M, Wang J, Karaesmen E, Rizvi A, Preus L, Tang H, Wang Y, Pooler L, Sheng X, Haiman CA, Van Den Berg D, Spellman SR, Wang T, Kuxhausen M, Chanock SJ, Lee SJ, Hahn TE, Sucheston-Campbell LE, Gadalla SM. Prognostic impact of pre-transplant chromosomal aberrations in peripheral blood of patients undergoing unrelated donor hematopoietic cell transplant for acute myeloid leukemia. Sci Rep. 2021 Jul 22;11(1):15004. PMCID: PMC8298542
202. Shadman M, Pasquini M, Ahn KW, Chen Y, Turtle CJ, Hematti P, Cohen JB, Khimani F, Ganguly S, Merryman RW, Yared JA, Locke FL, Ahmed N, Munshi PN, Beitinjaneh A, Reagan PM, Herrera AF, Sauter CS, Kharfan-Dabaja MA, Hamadani M. Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission. Blood. 2022 Mar 03;139(9):1330-1339. PMCID: PMC8900276
203. Heslop HE, Stadtmauer EA, Levine JE, Ballen KK, Chen YB, DeZern AE, Eapen M, Hamadani M, Hamilton BK, Hari P, Jones RJ, Logan BR, Kean LS, Leifer ES, Locke FL, Maziarz RT, Nemecek ER, Pasquini M, Phelan R, Riches ML, Shaw BE, Walters MC, Foley A, Devine SM, Horowitz MM. Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year. Transplant Cell Ther. 2021 Nov;27(11):885-907. PMCID: PMC8556300
204. Ciurea SO, Kongtim P, Soebbing D, Trikha P, Behbehani G, Rondon G, Olson A, Bashir Q, Gulbis AM, Indreshpal K, Rezvani K, Shpall EJ, Bassett R, Cao K, Martin AS, Devine S, Horowitz M, Pasquini M, Lee DA, Champlin RE. Decrease post-transplant relapse using donor-derived expanded NK-cells. Leukemia. 2022 Jan;36(1):155-164. PMCID: PMC8727305
205. Niederwieser D, Baldomero H, Bazuaye N, Bupp C, Chaudhri N, Corbacioglu S, Elhaddad A, Frutos C, Galeano S, Hamad N, Hamidieh AA, Hashmi S, Ho A, Horowitz MM, Iida M, Jaimovich G, Karduss A, Kodera Y, Kröger N, Péffault de Latour R, Lee JW, Martínez-Rolón J, Pasquini MC, Passweg J, Paulson K, Seber A, Snowden JA, Srivastava A, Szer J, Weisdorf D, Worel N, Koh MBC, Aljurf M, Greinix H, Atsuta Y, Saber W. One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. Haematologica. 2022 May 01;107(5):1045-1053. PMCID: PMC9052915
206. Wang J, Clay-Gilmour AI, Karaesmen E, Rizvi A, Zhu Q, Yan L, Preus L, Liu S, Wang Y, Griffiths E, Stram DO, Pooler L, Sheng X, Haiman C, Van Den Berg D, Webb A, Brock G, Spellman S, Pasquini M, McCarthy P, Allan J, Stölzel F, Onel K, Hahn T, Sucheston-Campbell LE. Genome-Wide Association Analyses Identify Variants in <i>IRF4</i> Associated With Acute Myeloid Leukemia and Myelodysplastic Syndrome Susceptibility. Front Genet. 2021;12:554948. PMCID: PMC8248805
207. Maiolino A, Costa LJ, Pasquini M, Crusoe EdQ, Vigorito AC, Salvino MA, Seguro FS, Filho JS, Hungria VTdM. Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. IV: CAR-T cell therapy for multiple myeloma patients Hematology, Transfusion and Cell Therapy. November 2021;43:S30-S34.
208. Luznik L, Pasquini MC, Logan B, Soiffer RJ, Wu J, Devine SM, Geller N, Giralt S, Heslop HE, Horowitz MM, Jones RJ, Litzow MR, Mendizabal A, Muffly L, Nemecek ER, O'Donnell L, O'Reilly RJ, Palencia R, Schetelig J, Shune L, Solomon SR, Vasu S, Ho VT, Perales MA. Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies. J Clin Oncol. 2022 Feb 01;40(4):356-368. PMCID: PMC8797487
209. Maiolino A, Costa LJ, Pasquini M, Crusoe EQ, Vigorito AC, Salvino MA, Seguro FS, Filho JS, Hungria VTM. Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. IV: CAR-T cell therapy for multiple myeloma patients. Hematol Transfus Cell Ther. 2021 Nov;43 Suppl 2(Suppl 2):S30-S34. PMCID: PMC8606706
210. Hahn T, Wang J, Preus LM, Karaesmen E, Rizvi A, Clay-Gilmour AI, Zhu Q, Wang Y, Yan L, Liu S, Stram DO, Pooler L, Sheng X, Haiman CA, Berg DVD, Webb A, Brock G, Spellman SR, Onel K, McCarthy PL, Pasquini MC, Sucheston-Campbell LE. Novel genetic variants associated with mortality after unrelated donor allogeneic hematopoietic cell transplantation. EClinicalMedicine. 2021 Oct;40:101093. PMCID: PMC8548922
211. Hamadani M, Gopal AK, Pasquini M, Kim S, Qiu X, Ahmed S, Lazaryan A, Bhatt VR, Daly A, Lulla P, Ciurea S, Gauthier J, Agrawal V, Grover NS, Lekakis L, Modi D, Dahi PB, Herr MM, Johnson PC, Hashmi H, Hematti P, Locke FL. Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis. Blood Adv. 2022 Jan 25;6(2):486-494. PMCID: PMC8791562
212. Zhang MJ, Pasquini MC, Ahn KW. Regression models in bone marrow transplantation - A case study Handbook of Survival Analysis. 19 April 2016:243-262.
213. Ciurea SO, Kongtim P, Soebbing D, Trikha P, Behbehani G, Rondon G, Olson A, Bashir Q, Gulbis AM, Indreshpal K, Rezvani K, Shpall EJ, Bassett R, Cao K, Martin AS, Devine S, Horowitz M, Pasquini M, Lee DA, Champlin RE. Decrease post-transplant relapse using donor-derived expanded NK-cells. Leukemia. 2022 Jan;36(1):155-164. PMCID: PMC8727305
214. Muhsen IN, Hashmi SK, Niederwieser D, Kroeger N, Agrawal S, Pasquini MC, Atsuta Y, Ballen KK, Seber A, Saber W, Kharfan-Dabaja MA, Rasheed W, Okamoto S, Khera N, Wood WA, Koh MBC, Greinix H, Kodera Y, Szer J, Horowitz MM, Weisdorf D, Aljurf M. Correction: Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries. Bone Marrow Transplant. 2020 Apr;55(4):837.
215. Dispenzieri A, Krishnan A, Arendt B, Blackwell B, Wallace PK, Dasari S, Vogl DT, Efebera Y, Fei M, Geller N, Giralt S, Hahn T, Howard A, Kohlhagen M, Landau H, Hari P, Pasquini MC, Qazilbash MH, McCarthy P, Shah N, Vesole DH, Stadtmauer E, Murray D. Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT). Blood Cancer J. 2022 Feb 10;12(2):27. PMCID: PMC8831597
216. Bashir Q, Nishihori T, Pasquini MC, Martens MJ, Wu J, Alsina M, Anasetti C, Brunstein C, Dawson P, Efebera Y, Gasparetto C, Geller N, Giralt S, Hall AC, Koreth J, McCarthy P, Scott E, Stadtmauer EA, Vesole DH, Hari P. A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial. Transplant Cell Ther. 2023 Jun;29(6):358.e1-358.e7. PMCID: PMC10442072
217. Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, Medvedova E, McCarthy PL, Libby EN, Voorhees PM, Orlowski RZ, Anderson LD Jr, Zonder JA, Milner CP, Gasparetto C, Agha ME, Khan AM, Hurd DD, Gowin K, Kamble RT, Jagannath S, Nathwani N, Alsina M, Cornell RF, Hashmi H, Campagnaro EL, Andreescu AC, Gentile T, Liedtke M, Godby KN, Cohen AD, Openshaw TH, Pasquini MC, Giralt SA, Kaufman JL, Yee AJ, Scott E, Torka P, Foley A, Fulciniti M, Hebert K, Samur MK, Masone K, Maglio ME, Zeytoonjian AA, Nadeem O, Schlossman RL, Laubach JP, Paba-Prada C, Ghobrial IM, Perrot A, Moreau P, Avet-Loiseau H, Attal M, Anderson KC, Munshi NC, DETERMINATION Investigators. Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. N Engl J Med. 2022 Jul 14;387(2):132-147. PMCID: PMC10040899
218. Jacobson CA, Locke FL, Ma L, Asubonteng J, Hu ZH, Siddiqi T, Ahmed S, Ghobadi A, Miklos DB, Lin Y, Perales MA, Lunning MA, Herr MM, Hill BT, Ganguly S, Dong H, Nikiforow S, Hooper M, Kawashima J, Xu H, Pasquini MC. Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States. Transplant Cell Ther. 2022 Sep;28(9):581.e1-581.e8. PMCID: PMC9427701
219. Holstein SA, Asimakopoulos F, Azab AK, Bianchi G, Bhutani M, Crews LA, Cupedo T, Giles H, Gooding S, Hillengass J, John L, Kaiser S, Lee L, Maclachlan K, Pasquini MC, Pichiorri F, Shah N, Shokeen M, Shy BR, Smith EL, Verona R, Usmani SZ, McCarthy PL. Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma. Transplant Cell Ther. 2022 Aug;28(8):446-454. PMCID: PMC9357156
220. Broglie L, Friend BD, Chhabra S, Bupp C, Schiller GJ, Logan B, Pasquini MC, Savani B, Stadtmauer EA, Thakar MS, Sorror M. Differential use of the hematopoietic cell transplantation-comorbidity index among adult and pediatric transplant physicians. Leuk Lymphoma. 2022 Oct;63(10):2507-2510. PMCID: PMC9875328
221. D'Souza A, Brazauskas R, Stadtmauer EA, Pasquini MC, Hari P, Bashey A, Callander N, Devine S, Efebera Y, Ganguly S, Gasparetto C, Geller N, Horowitz MM, Koreth J, Landau H, Brunstein C, McCarthy P, Qazilbash MH, Giralt S, Krishnan A, Flynn KE. Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma. Am J Hematol. 2023 Jan;98(1):140-147. PMCID: PMC9659666
222. Phelan R, Chen M, Bupp C, Bolon YT, Broglie L, Brunner-Grady J, Burns LJ, Chhabra S, Christianson D, Cusatis R, Devine SM, D'Souza A, Eapen M, Hamadani M, Hengen M, Lee SJ, Moskop A, Page KM, Pasquini M, Pérez WS, Riches M, Rizzo D, Saber W, Spellman SR, Stefanski HE, Steinert P, Weisdorf D, Horowitz M, Auletta JJ, Shaw BE, Arora M. Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes. Transplant Cell Ther. 2022 Jul;28(7):409.e1-409.e10. PMCID: PMC9840526
223. Patel SS, Ahn KW, Khanal M, Bupp C, Allbee-Johnson M, Majhail NS, Hamilton BK, Rotz SJ, Hashem H, Beitinjaneh A, Lazarus HM, Krem MM, Prestidge T, Bhatt NS, Sharma A, Gadalla SM, Murthy HS, Broglie L, Nishihori T, Freytes CO, Hildebrandt GC, Gergis U, Seo S, Wirk B, Pasquini MC, Savani BN, Sorror ML, Stadtmauer EA, Chhabra S. Noninfectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2022 Jun;28(6):310-320. PMCID: PMC9197865
224. Abou-Ismail MY, Fraser R, Allbee-Johnson M, Metheny L 3rd, Ravi G, Ahn KW, Bhatt NS, Lazarus HM, de Lima M, El Jurdy N, Hematti P, Beitinjaneh AM, Nishihori T, Badawy SM, Sharma A, Pasquini MC, Savani BN, Sorror ML, Stadtmauer EA, Chhabra S. Does recipient body mass index inform donor selection for allogeneic haematopoietic cell transplantation? Br J Haematol. 2022 May;197(3):326-338. PMCID: PMC9675037
225. Stewart MD, McCall B, Pasquini M, Yang AS, Britten CD, Chuk M, De Claro RA, George B, Gormley N, Horowitz MM, Kowack E, McCoy C, Morrow PK, Okoye E, Ricafort R, Rossi J, Sharon E, Theoret M, Vegni F, Yu T, Allen J. Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials. Cytotherapy. 2022 Jul;24(7):742-749. PMCID: PMC9721456
226. Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Rizzo JD, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M. Corrigendum to 'Ixazomib for chronic Graft-Versus-Host Disease prophylaxis following allogeneic hematopoietic cell transplantation' [Biology of Blood and Marrow Transplantation 26/10 (2020) 1876-1885]. Transplant Cell Ther. 2022 Oct;28(10):717.
227. D'Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, Devine S, Eapen M, Hamadani M, Hari P, Pasquini MC, Perez W, Phelan RA, Riches ML, Rizzo JD, Saber W, Shaw BE, Spellman SR, Steinert P, Weisdorf DJ, Horowitz MM. Corrigendum to 'Current Use and Trends in Hematopoietic Cell Transplantation in the United States' [Transplantation and Cellular Therapy 26/8 (2020) e177-e182]. Transplant Cell Ther. 2022 Oct;28(10):715-716.
228. Myers RM, Jacoby E, Pulsipher MA, Pasquini MC, Grupp SA, Shah NN, Laetsch TW, Curran KJ, Schultz LM. INSPIRED Symposium Part 1: Clinical Variables Associated with Improved Outcomes for Children and Young Adults treated with Chimeric Antigen Receptor T cells for B cell Acute Lymphoblastic Leukemia. Transplant Cell Ther. 2023 Oct;29(10):598-607.
229. Mohan M, Janz S, Brazauskas R, Dwinell MB, Teng BQ, Yun G, Dong J, Pasquini MC, Giralt S, Landau H, Stadtmauer E, Krishnan A, D'Souza A. Increased CXCL10 is seen at 1-year after autologous hematopoietic cell transplantation in multiple myeloma patients on maintenance lenalidomide therapy. Bone Marrow Transplant. 2023 Aug;58(8):953-955. PMCID: PMC10555486
230. Jadi O, Tang H, Olsen K, Vensko S, Zhu Q, Wang Y, Haiman CA, Pooler L, Sheng X, Brock G, Webb A, Pasquini MC, McCarthy PL, Spellman SR, Hahn T, Vincent B, Armistead P, Sucheston-Campbell LE. Associations of minor histocompatibility antigens with outcomes following allogeneic hematopoietic cell transplantation. Am J Hematol. 2023 Jun;98(6):940-950. PMCID: PMC10368187
231. Auletta JJ, Kou J, Chen M, Bolon YT, Broglie L, Bupp C, Christianson D, Cusatis RN, Devine SM, Eapen M, Hamadani M, Hengen M, Lee SJ, Moskop A, Page KM, Pasquini MC, Perez WS, Phelan R, Riches ML, Rizzo JD, Saber W, Spellman SR, Stefanski HE, Steinert P, Tuschl E, Yusuf R, Zhang MJ, Shaw BE. Real-World Data Showing Trends and Outcomes by Race and Ethnicity in Allogeneic Hematopoietic Cell Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. Transplant Cell Ther. 2023 Jun;29(6):346.e1-346.e10. PMCID: PMC10239334
232. Nikiforow S, Frigault MJ, Frey NV, Gardner RA, Komanduri KV, Perales MA, Kebriaei P, Warkentin PI, Pasquini M, Aho JL, Levine BL, Heslop HE, Hlucky TL, Habucky K, Gharibo M, Jagasia M, Locke FL. Paving the Road for Chimeric Antigen Receptor T Cells: American Society for Transplantation and Cellular Therapy 80/20 Task Force Consensus on Challenges and Solutions to Improving Efficiency of Clinical Center Certification and Maintenance of Operations for Commercially Approved Immune Effector Cell Therapies. Transplant Cell Ther. 2023 Apr;29(4):228-239.
233. Chorão P, Montoro J, Balaguer-Roselló A, Guerreiro M, Villalba M, Facal A, Solves P, Gómez-Segui I, Pasquini MC, Granados P, Bataller A, Louro A, de la Rubia J, Sanz MA, Sanz J. T Cell-Depleted Peripheral Blood versus Unmanipulated Bone Marrow in Matched Sibling Transplantation for Aplastic Anemia. Transplant Cell Ther. 2023 May;29(5):322.e1-322.e5.
234. Akinola IM, Cusatis R, Pasquini MC, Shaw BE, Bollu V, Dalal A, Tesfaye M, Flynn KE. Multi-Stakeholder Qualitative Interviews to Inform Measurement of Patient Reported Outcomes After CAR-T. Transplant Cell Ther. 2023 Apr;29(4):254.e1-254.e9. PMCID: PMC10369368
235. Tokaz MC, Baldomero H, Cowan AJ, Saber W, Greinix H, Koh MBC, Kröger N, Mohty M, Galeano S, Okamoto S, Chaudhri N, Karduss AJ, Ciceri F, Colturato VAR, Corbacioglu S, Elhaddad A, Force LM, Frutos C, León AG, Hamad N, Hamerschlak N, He N, Ho A, Huang XJ, Jacobs B, Kim HJ, Iida M, Lehmann L, de Latour RP, Percival MM, Perdomo M, Rasheed W, Schultz KR, Seber A, Ko BS, Simione AJ, Srivastava A, Szer J, Wood WA, Kodera Y, Nagler A, Snowden JA, Weisdorf D, Passweg J, Pasquini MC, Sureda A, Atsuta Y, Aljurf M, Niederwieser D. An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia. Transplant Cell Ther. 2023 Apr;29(4):279.e1-279.e10.
236. Olsen KS, Jadi O, Dexheimer S, Bortone DS, Vensko SP, Bennett S, Tang H, Diiorio M, Saran T, Dingfelder D, Zhu Q, Wang Y, Haiman CA, Pooler L, Sheng X, Webb A, Pasquini MC, McCarthy PL, Spellman SR, Weimer E, Hahn T, Sucheston-Campbell L, Armistead PM, Vincent BG. Shared graft-versus-leukemia minor histocompatibility antigens in DISCOVeRY-BMT. Blood Adv. 2023 May 09;7(9):1635-1649. PMCID: PMC10182302
237. D'Souza A, Brazauskas R, Teng BQ, Yun G, Uttley H, Dong J, Dwinell MB, Pasquini MC, Giralt S, Landau H, Stadtmauer E, Krishnan A, Janz S. DNA methylation in circulating leukocytes is a novel biomarker in multiple myeloma. Bone Marrow Transplant. 2023 Mar;58(3):334-336.
238. Friend BD, Broglie L, Logan BR, Chhabra S, Bupp C, Schiller G, Beitinjaneh A, Perez MAD, Guilcher GMT, Hashem H, Hildebrandt GC, Krem MM, Lazarus HM, Nishihori T, Nusrat R, Rotz SJ, Wirk B, Wieduwilt M, Pasquini M, Savani BN, Stadtmauer EA, Sorror ML, Thakar MS. Adapting the HCT-CI Definitions for Children, Adolescents, and Young Adults with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2023 Feb;29(2):123.e1-123.e10. PMCID: PMC9911376
239. Broglie L, Friend BD, Chhabra S, Logan BR, Bupp C, Schiller G, Savani BN, Stadtmauer E, Abraham AA, Aljurf M, Badawy SM, Perez MAD, Guinan EC, Hashem H, Krem MM, Lazarus HM, Rotz SJ, Wirk B, Yared JA, Pasquini M, Thakar MS, Sorror ML. Expanded HCT-CI Definitions Capture Comorbidity Better for Younger Patients of Allogeneic HCT for Nonmalignant Diseases. Transplant Cell Ther. 2023 Feb;29(2):125.e1-125.e9. PMCID: PMC9911359
240. Goldman A, Raschi E, Chapman J, Santomasso BD, Pasquini MC, Perales MA, Shouval R. Progressive multifocal leukoencephalopathy in patients treated with chimeric antigen receptor T cells. Blood. 2023 Feb 09;141(6):673-677. PMCID: PMC9979708
241. Zheng D, Sato S, Arima H, Heeley E, Delcourt C, Cao Y, Chalmers J, Anderson CS, INTERACT2 Investigators. Estimated GFR and the Effect of Intensive Blood Pressure Lowering After Acute Intracerebral Hemorrhage. Am J Kidney Dis. 2016 Jul;68(1):94-102.

© 2024 Clinical & Translational Science Institute
Medical College of Wisconsin
8701 Watertown Plank Road
Milwaukee, WI 53223

Publication and ontology data from NCBI | Disclaimer and Copyright

This site is a collaborative effort of the Medical College of Wisconsin and the Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number 2UL1TR001436) at the National Institutes of Health (NIH).

Faculty Collaboration Database

Profiles for MCW, MU, MSOE, UWM, BCW, CW, Froedtert, and VA Faculty